Information on EC 3.4.22.15 - cathepsin L

New: Word Map on EC 3.4.22.15
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY
3.4.22.15
-
RECOMMENDED NAME
GeneOntology No.
cathepsin L
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
similar to that of papain. As compared to cathepsin B, cathepsin L exhibits higher activity towards protein substrates, but has little activity on Z-Arg-Arg-NHMec, and no peptidyl-dipeptidase activity
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis
-
-
hydrolysis of peptide bond
-
-
hydrolysis of peptide bond
-
-
hydrolysis of peptide bond
-
-
endopeptidase
-
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
AgCatL
-
-
Aldrichina grahami cysteine proteinase
-
-
-
-
cat L
P07711
-
Cat L-A
Q9XYL8
-
cath-L
-
-
cathepsin L
-
-
cathepsin L
P07711
-
cathepsin L
-
-
cathepsin L
P06797
-
cathepsin L
-
-
cathepsin L
-
-
cathepsin L isoform CRA-b
Q9HBQ7
splice variant encoding a truncated form of cathepsin L
cathepsin L-A
-
enzyme splicing variant
cathepsin L-A1
-
enzyme splicing variant
cathepsin L-A2
-
enzyme splicing variant
cathepsin L-A3
-
enzyme splicing variant
cathepsin L-B
-
enzyme splicing variant
cathepsin L-like
E5DHH4
-
cathepsin L-like enzyme
-
-
cathepsin-L
-
-
cathepsin-L
P07711
-
cathepsin-L T2V
P07711
-
CatL
E3TGS2
-
CatL
Q7Z0G9
-
CATL A IV
Q9HBQ7
-
CatL1G
-
juvenile isoform
CatL5
-
adult isoform
CPL
Q6DMN0
-
cpl-1
Meloidogyne incognita J2
-
-
-
CTSL
E1UJ48
-
CTSL1
-
-
Cwp84
Peptoclostridium difficile 79-685
Q83UF3
-
-
human cathepsin L
-
-
major excreted protein
-
-
-
-
MEP
-
-
-
-
PDP
-
-
-
-
progesterone-dependent protein
-
-
-
-
SMCL1
-
-
-
-
sperm-histone protease
-
-
CAS REGISTRY NUMBER
COMMENTARY
60616-82-2
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Agama stellio stellio
-
-
-
Manually annotated by BRENDA team
jumbo squid
-
-
Manually annotated by BRENDA team
Chinese mitten crab
UniProt
Manually annotated by BRENDA team
cotton bollworm
UniProt
Manually annotated by BRENDA team
infected with Anaplasma phagocytophilum
-
-
Manually annotated by BRENDA team
patients with colorectal cancer
-
-
Manually annotated by BRENDA team
patients with coronary heart disease
-
-
Manually annotated by BRENDA team
procathepsin L
UniProt
Manually annotated by BRENDA team
up-regulation of catfish cathepsin H and L transcripts during the early stage of Edwardsiella ictaluri infection
UniProt
Manually annotated by BRENDA team
Meloidogyne incognita J2
strain J2
-
-
Manually annotated by BRENDA team
mud loach
UniProt
Manually annotated by BRENDA team
novascularization is significantly impaired in cathepsin L-deficient mice
-
-
Manually annotated by BRENDA team
Peptoclostridium difficile 79-685
-
UniProt
Manually annotated by BRENDA team
cathepsin L1 and L2
-
-
Manually annotated by BRENDA team
Italian Large White breed
UniProt
Manually annotated by BRENDA team
strain RH
UniProt
Manually annotated by BRENDA team
strain RH
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
ablation of cathepsin L in a cystatin M/E-deficient background (Cst6-/-Ctsl-/-double-knockout mice) restores viability and results in normalization of stratum corneum morphology
malfunction
-
cathepsin L knockout mouse brains show extensive decreases in dynorphin A, dynorphin B, and alpha-neoendorphin that are reduced by 75%, 83%, and 90%, respectively
malfunction
-
cathepsin L pharmacological inhibition significantly attenuates lysosomal membrane permeabilization, mitochondrial membrane permeabilization, and apoptosis
malfunction
-
deficiency for cathepsin L promotes enhanced tumor progression and metastasis in mouse epidermis, Ctsl deficiency potentiates neoplastic progression in K14-HPV16 transgenic mice but does not alter immune cell infiltration or angiogenesis during neoplastic progression in HPV16 mice
malfunction
-
in cathepsin L knockout mice, cholecystokinin 8 levels are substantially reduced in brain cortex by an average of 75%
malfunction
-
inhibition of cathepsin L by specific inhibitors results in a significant decrease of intraocular neovascularization, a similar decrease of neovascularization is found in cathepsin L-deficient mice
malfunction
-
inhibition of cathepsin L can decrease metastatic tumor development
malfunction
-
inhibition of cathepsin L results in a decrease in tumor cell migration
malfunction
-
severity of pancreatitis is reduced in cathepsin L-deficient mice, whereas apoptosis and intrapancreatic trypsin activity are increased
malfunction
-
in cathepsin L knockou mice, brain levels of (Met)enkephalin are reduced to 44%, brain levels of neuropeptide Y are reduced to 22%, brain levels of cholecystokinin are reduced to 75%, brain levels of dynorphin A are reduced to 25% , brain levels of dynorphin B are reduced to 17%, brain levels of alpha-neoendorphin are reduced to 10%, brain levels of adrenocorticotropin hormone are reduced to 23%, brain levels of beta-endorphin are reduced to 18%, and brain levels of alpha-MSH are reduced to 7% of the wild type level
physiological function
-
cat L mediates resveratrol-induced apoptotic cell death in cervical cancer cells
physiological function
-
cathepsin L does not seem to play a general role in the degradation of proteins in the lumen of autophagosomes, but is involved more specifically in the degradation of autophagosomal membrane markers
physiological function
-
cathepsin L functions as a major protease responsible for cholecystokinin 8 production in mouse brain cortex, and participates with prohormone convertase 1/3 for cholecystokinin 8 production in pituitary cells
physiological function
-
cathepsin L inactivates trypsinogen and counteracts the ability of cathepsin B to form active trypsin
physiological function
-
cathepsin L is involved in bone remodeling processes and contributes to facilitate bone metastasis formation
physiological function
-
cathepsin L is required for ecotropic murine leukemia virus infection in NIH-3T3 cells
physiological function
-
cathepsin L plays a critical role in intraocular angiogenesis
physiological function
-
cathepsin L plays a minimal, if any, role in Ebola virus infection in human dendritic cells
physiological function
-
cathepsin L plays a prominent role, jointly with PC1/3 and PC2, for production of dynorphins in brain
physiological function
-
cathepsin L plays a role in the immune system, in particular by degrading the invariant chain in MHC class II processing. Cathepsin L plays a part in recycling processes during axon outgrowth and synapse formation in the developing postnatal central nervous system
physiological function
-
CatL cleavage of Zaire Ebola virus glycoprotein exposes its receptor-binding domain, thereby facilitating access to a putative cellular receptor in steps that lead to membrane fusion
physiological function
-
Ctsl is critical for the termination of growth factor signaling in the endosomal/lysosomal compartment of keratinocytes and, therefore, functions as an anti-tumor protease
physiological function
-
granule-bound cathepsins are essential for processing perforin to its active form, and CatL is an important, but not exclusive, participant in this process
physiological function
-
the cystatin M/E-cathepsin L balance is essential for tissue homeostasis in epidermis, hair follicles, and cornea. Activation of cathepsin D and transglutaminase-1 are downstream events, dependent of cathepsin L activity
physiological function
-
cathepsin L in secretory vesicles functions as a key protease for proteolytic processing of proneuropeptides (including enkephalin, neuropeptide Y, dynorphins, cholecystokinin, and others) and prohormones into active neuropeptides that are released to mediate cell-cell communication in the nervous system for neurotransmission. Cathepsin L is a key protease responsible for cholecystokinin 8 production in brain
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(benzyloxycarbonyl-Phe-Arg)2-R110 + H2O
?
show the reaction diagram
-
rhodamine-labeled substrate
-
-
?
2-aminobenzoic acid-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ala + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Ala-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Arg-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Arg-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Asn-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Asn-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Gln-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Gln-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Glu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Gly-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Gly-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-His-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-His-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ile-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Ile-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Leu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Leu-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Arg-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Arg-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Asn-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Asn-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Asp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Asp-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Gln-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Gln-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Glu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Glu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Gly-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Gly-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-His-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-His-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Ile-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Ile-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Leu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Leu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Phe-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Phe-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Pro-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Pro-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Leu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Leu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Phe-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Phe-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Arg-Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Arg + Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Asn-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Asn + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Asp-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Asp + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Gln-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Gln + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Glu-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Glu + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Gly-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Gly + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-His-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-His + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Ile-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ile + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Lys-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Lys + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Met-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Met + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Phe-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Phe + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Pro-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Pro + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Ser-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Ser + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Thr-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Thr + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Leu-Val-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Leu-Val + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys + Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Met-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Met-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Phe-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Phe-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Pro-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Pro-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Ser-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Ser-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Thr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Thr-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Trp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Trp-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Tyr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Tyr-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Lys-Val-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Lys-Val-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Ile-Trp-NH2 + H2O
2-aminobenzoyl-Met-Ile-Ser-Leu-Met-Lys + Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg + 2-aminobenzoyl-Met-Ile-Ser-Leu-Met + Lys-Arg-Pro-Pro-Gly-Trp-Ser-Pro-Phe-Arg + Ser-Ser-Arg-Ile-Trp-NH2
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Phe-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Phe-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Val-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine + H2O
2-aminobenzoyl-Val-Leu-Arg + Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
-
?
3-carboxypropionyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
48 kDa intermediate of cathepsin D + H2O
34 kDa mature cathepsin D + ?
show the reaction diagram
-
-
-
-
?
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-PRKQLATKAARKSAK-Dnp + H2O
?
show the reaction diagram
-
-
-
-
?
actomyosin + H2O
?
show the reaction diagram
-
endogenous cathepsin L of red bulleye surimi participates in gel disintegration during kamaboko processing by degrading the myosin heavy chain of actomyosin and consequently hindering the gelation of red bulleye surimi
-
-
?
Albumin + H2O
?
show the reaction diagram
-
-
-
-
?
Albumin + H2O
?
show the reaction diagram
-
isoform CatL5 shows weak activity against albumin
-
-
?
alpha-casein + H2O
?
show the reaction diagram
-
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
no activity
-
-
-
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
azocasein + H2O
?
show the reaction diagram
-
low activity
-
-
?
BAM-22P + H2O
(Met)enkephalin + ?
show the reaction diagram
-
-
-
-
?
benzoyl-Arg-2-naphthylamide + H2O
benzoyl-Arg + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
benzoyl-Arg-4-nitroanilide + H2O
benzoyl-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzoyl-Phe-Ala-Arg-4-methoxy-2-naphtylamide + H2O
benzoyl-Phe-Ala-Arg + 4-methoxy-2-naphtylamine
show the reaction diagram
E3TGS2
-
-
-
?
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
-
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
7% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
no activity
-
-
-
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
no activity
-
-
-
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
weak activity
-
-
?
benzyloxycarbonyl-Arg-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
weak activity
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
9% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
A5HJW4
28.61% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Arg-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Arg-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
A5HJW4
88.77% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-L-citrulline-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-L-citrulline 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Leu-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Leu-L-Leu-L-Glu-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Leu-L-Leu-L-Glu + 7-amino-4-methylcoumarin
show the reaction diagram
A5HJW4
76.66% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-4-nitroanilide + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 4-nitroaniline
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
Q6DMN0
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
A5HJW4
100% activity
-
-
?
benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-trifluoromethylcoumarin + H2O
benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-trifluoromethylcoumarin
show the reaction diagram
-
cathepsin L specific synthetic substrate
-
-
?
benzyloxycarbonyl-Leu-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Leu-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methyl-coumarin
show the reaction diagram
-
-
-
-
-
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Lys-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Lys-Gln-Lys-Leu-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
preferred substrate
-
-
?
benzyloxycarbonyl-Lys-p-nitrophenyl ester + H2O
benzyloxycarbonyl-Lys + 4-nitrophenol
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Ala-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methoxy-beta-naphthylamide + H2O
benzyloxycarbonyl-Phe-Arg + 4-methoxy-beta-naphthylamine
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-nitroanilide + H2O
?
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
P07711
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
Agama stellio stellio
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
Q6UB44
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
100% activity
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
substrate for both cathepsin L and cathepsin B
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amido-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-Val-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
casein + H2O
?
show the reaction diagram
-
-
-
-
?
cathepsin D + H2O
?
show the reaction diagram
-
-
-
-
?
CCAAT-displacement protein/cut homeobox protein + H2O
p90 isoform of CCAAT-displacement protein/cut homeobox protein + p110 isoform of CCAAT-displacement protein/cut homeobox protein + ?
show the reaction diagram
-
-
-
-
?
CCALNNGGGALVPRGSGTAK-(5-carboxyfluorescein)-NH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Cholecystokinin + H2O
?
show the reaction diagram
-
-
-
-
?
chromogranin A + H2O
catestatin fragments + ?
show the reaction diagram
-
-
-
-
?
chromogranin A + H2O
catestatin
show the reaction diagram
-
-
-
-
?
Collagen + H2O
?
show the reaction diagram
-
-
-
-
?
Collagen + H2O
?
show the reaction diagram
-
-
-
-
?
Collagen + H2O
?
show the reaction diagram
-
selective cleavage of terminal peptides leads to conversion of beta- and higher components mainly to alpha-chains
-
-
?
Collagen + H2O
?
show the reaction diagram
-
conversion of cross-linked beta-chain dimers into uncross-linked alpha-chain monomers
-
-
?
Collagen + H2O
?
show the reaction diagram
-
substrate for cathepsin L mutant A205L
-
-
?
collagen type IV + H2O
?
show the reaction diagram
-
-
-
-
?
collagen XVIII + H2O
endostatin + ?
show the reaction diagram
-
-
-
-
?
CUX1 transcription factor + H2O
?
show the reaction diagram
-
-
-
-
?
CV-(L-Phe-Arg)2 + H2O
?
show the reaction diagram
-
-
-
-
?
D-Val-Leu-Arg-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
D-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O
D-Val-Leu-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Disrupted in renal carcinoma 2 + H2O
?
show the reaction diagram
-
the substrate is proteolytically processed into a N-glycosylated N-terminal and a non-glycosylated C-terminal fragment, respectively. The cleavage site is between amino acid residues 214 and 261
-
-
?
dynamin + H2O
?
show the reaction diagram
-
CatL is highly reactive toward recombinant dynamin at pH 5.0 and 6.0
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
Elastin + H2O
?
show the reaction diagram
-
-
-
-
?
Elastin + H2O
?
show the reaction diagram
-
tritiated elastin
-
-
?
Elastin + H2O
?
show the reaction diagram
-
the enzyme shows distinctive preferences in degrading elastins from bovine neck ligament, aorta, and lung
-
-
?
endorepellin + H2O
anti-apoptotic C-terminal fragment of endorepellin + ?
show the reaction diagram
-
recombinant endorepellin is an in vitro substrate. Inhibition of cathepsin L activity in endothelial cells exposed to pro-apoptotic stimuli prevents release of anti-apoptotic C-terminal fragment of endorepellin without modulating the development of apoptosis. Inhibition of caspase-3 activation in endothelial cells concomitantly prevents cathepsin L release, production of anti-apoptotic C-terminal fragment of endorepellin, and the development of paracrine anti-apoptotic activity, recombinant endorepellin is an in vitro substrate
-
-
?
epidermal growth factor receptor + H2O
?
show the reaction diagram
-
-
-
-
?
Fibrinogen + H2O
?
show the reaction diagram
-
-
-
-
?
fibronectin + H2
?
show the reaction diagram
Peptoclostridium difficile, Peptoclostridium difficile 79-685
Q83UF3
-
enzyme cleaves fibronectin to produce two bands
-
?
Fibronectin + H2O
?
show the reaction diagram
-
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
-
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
-
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
-
cleavage occurs only at pH 5.5
-
-
?
GABARAP-II protein + H2O
?
show the reaction diagram
-
-
-
-
?
gamma-globulin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
E5DHH4
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
low activity
-
-
?
Gelatin + H2O
?
show the reaction diagram
A5HJW4
on gelatin-zymography, the purified pro-mature enzyme of cathepsin L is capable of hydrolyzing 0.1% gelatin at pH 7.5
-
-
?
Glucagon + H2O
?
show the reaction diagram
-
-
-
-
?
glycogen phosphorylase + H2O
?
show the reaction diagram
-
-
-
-
?
H2N-Abz-DLVGDVRLAGV-3-nitroYA-CONH2 + H2O
?
show the reaction diagram
-
-
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
-
-
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
-
-
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
-
-
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
Agama stellio stellio
-
-
-
?
histone + H2O
?
show the reaction diagram
-
-
-
-
?
histone H1 + H2O
?
show the reaction diagram
-
-
-
-
?
histone H3 + H2O
?
show the reaction diagram
-
-
-
-
?
histone H3 + H2O
?
show the reaction diagram
-
during embryonic stem cell differentiation, histone H3 is proteolytically cleaved at its N-terminus. H3 cleavage may be regulated by covalent modifications present on the histone tail itself
-
-
?
Immunoglobulin + H2O
?
show the reaction diagram
-
-
-
-
?
insulin + H2O
?
show the reaction diagram
-
-
-
-
?
Insulin B-chain + H2O
?
show the reaction diagram
Agama stellio stellio
-
-
-
?
Insulin B-chain + H2O
?
show the reaction diagram
-
preferential cleavage at: Glu13-Ala14, Leu17-Val18, and Tyr26-Thr27
-
-
?
Insulin B-chain + H2O
?
show the reaction diagram
-
main cleavage sites: Glu13-Ala14 and Tyr26-Thr27, minor cleavage sites: Val2-Asn3, Asn3-Gln4, Cys7-Glu8, Tyr16-Leu17, Leu17-Val18
-
-
?
insulin receptor + H2O
?
show the reaction diagram
-
-
-
-
?
insulin-like growth factor-1 receptor + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-8 precursor + H2O
?
show the reaction diagram
-
enzyme plays an important role in IL-8 processing in inflammatory sites
-
?
Kininogen + H2O
Kinin
show the reaction diagram
-
-
-
-
?
Kininogen + H2O
Kinin
show the reaction diagram
-
high and low molecular weight kininogen
-
?
L-Ala-L-Ala-L-Phe-7-amido-4-methylcoumarin + H2O
L-Ala-L-Ala-L-Phe + 7-amino-4-methylcoumarin
show the reaction diagram
A5HJW4
28.66% activity compared to benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
-
?
L-arginine 7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
very poor substrate
-
-
?
L-lactate dehydrogenase + H2O
?
show the reaction diagram
-
-
-
-
?
L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
L-Leu-L-Arg + 7-amido-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
preferred substrate for isoform CatL5
-
-
?
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
L-pyroglutamyl-L-Phe-Leu-p-nitroanilide + H2O
L-pyroglutamyl-L-Phe-Leu + p-nitroaniline
show the reaction diagram
Meloidogyne incognita, Meloidogyne incognita J2
-
-
-
-
?
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin + H2O
L-Val-L-Leu-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
laminin + H2
?
show the reaction diagram
Peptoclostridium difficile, Peptoclostridium difficile 79-685
Q83UF3
-
-
-
?
Laminin + H2O
?
show the reaction diagram
-
-
-
-
?
Laminin + H2O
?
show the reaction diagram
-
cleavage occurs only at pH 5.5
-
-
?
LC3-II protein + H2O
?
show the reaction diagram
-
-
-
-
?
Leu-Trp-Met-Arg-Phe-Ala + H2O
Leu-Trp-Met + Arg-Phe-Ala
show the reaction diagram
-
-
-
?
Leu-Tyr-methylcoumarin 7-amide + H2O
Leu-Tyr + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
methionine enkephalin-Arg-Arg + H2O
?
show the reaction diagram
-
-
-
-
?
myosin + H2O
?
show the reaction diagram
-
-
-
-
?
myosin heavy chain + H2O
?
show the reaction diagram
-
-
-
-
?
N-benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
N-benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
N-benzyloxycarbonyl-Phe-Arg-2-(4-methoxynaphthylamide) + H2O
N-benzyloxycarbonyl-Phe-Arg + 4-methoxy-2-naphthylamine
show the reaction diagram
-
-
-
-
?
N-carbobenzoxy-L-arginine-L-arginine 7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
7% of the activity with N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin
-
-
?
N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin + H2O
?
show the reaction diagram
-
-
-
-
?
N2-benzoyl-L-argininamide + H2O
NH3 + N2-benzoyl-L-arginine
show the reaction diagram
-
-
-
?
Nalpha-benzyloxycarbonyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
Nalpha-benzyloxycarbonyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
E5DHH4
-
-
-
?
Nipah virus fusion protein + H2O
?
show the reaction diagram
-
cathepsin L specifically converts Nipah virus fusion protein to a mature and fusogenic form
-
-
?
Nipah virus fusion protein + H2O
?
show the reaction diagram
-
proteolytically processed within endosomes by cathepsin L
-
-
?
perforin + H2O
?
show the reaction diagram
-
CatL preferentially cleaves a site on full-length recombinant perforin close to its C terminus
-
-
?
phosphorylase a + H2O
?
show the reaction diagram
-
-
-
-
?
precursor form 77IL-8 of interleukin-8 + H2O
precursor form 72IL-8 of interleukin-8 + ?
show the reaction diagram
-
cleavage between Arg5 and Ser6
-
?
pro-dipeptidyl peptidase I
?
show the reaction diagram
-
cleavage at K133, cathepsin L could be an important activator of dipeptidyl peptidase I in vivo
-
?
pro-dynorphin + H2O
?
show the reaction diagram
-
-
-
-
?
pro-enkephalin + H2O
enkephalin + ?
show the reaction diagram
-
-
-
-
?
pro-neuropeptide Y + H2O
neuropeptide Y + ?
show the reaction diagram
-
cathepsin L cleaves pro-neuropeptide Y (1-70) to generate neuropeptide Y-Gly (1-38) and the COOH-terminal peptide fragment (39-70)
-
-
?
Pro-opiomelanocortin + H2O
?
show the reaction diagram
-
-
-
-
?
Pro-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
Pro-Phe-Arg-4-methylcoumarin 7-amide + H2O
Pro-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
-
pro-urokinase plasminogen activator + H2O
?
show the reaction diagram
-
-
-
-
?
procathepsin L + H2O
cathepsin L + ?
show the reaction diagram
P07711
autoactivation
-
-
?
proheparanase + H2O
active form of heparanase + ?
show the reaction diagram
-
removal of the linker peptide and conversion of proheparanase into its active 8 + 50-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
proheparanase + H2O
active form of heparanase + ?
show the reaction diagram
-
removal of the linker peptide and conversion of proheparanase into its active 850-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
secretory leukocyte protease inhibitor + H2O
?
show the reaction diagram
-
incubation of recombinant secretory leukocyte protease inhibitor with cathepsin L leads to complete loss of activity while encapsulation of recombinant secretory leukocyte protease inhibitor in 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine]-cholesterol liposomes retains 92.6% of its activity after challenge with cathepsin L
-
-
?
serum albumin + H2O
?
show the reaction diagram
-
-
-
-
?
serum albumin + H2O
?
show the reaction diagram
-
-
-
-
?
serum albumin + H2O
?
show the reaction diagram
Agama stellio stellio
-
-
-
?
succinyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
succinyl-Ala-Phe-Lys-4-methylcoumarin 7-amide + H2O
succinyl-Ala-Phe-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
succinyl-Leu-Leu-Val-Tyr-methylcoumarin 7-amide + H2O
succinyl-Leu-Leu-Val-Tyr + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
succinyl-Tyr-Met-2-naphthylamide + H2O
?
show the reaction diagram
-
-
-
-
?
surimi protein + H2O
?
show the reaction diagram
-
-
-
-
?
tert-butoxycarbonyl-Arg-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Arg-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butoxycarbonyl-Arg-Val-Arg-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Arg-Val-Arg-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butoxycarbonyl-Val-Pro-Arg-methylcoumarin 7-amide + H2O
tert-butoxycarbonyl-Val-Pro-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Gln-Ala-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide + H2O
?
show the reaction diagram
-
-
-
-
?
tert-butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Val-Leu-Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
1% activity compared to benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
thyroglobulin type-1 domain + H2O
?
show the reaction diagram
-
the thyroglobulin type-1 domain is a protein module that occurs in a variety of secreted and membrane proteins and is recognised as a potent inhibitor of cysteine proteases. Nevertheless, at high enzyme and inhibitor concentrations in the mircomolar range cathepsin L degrades thyroglobulin type-1 domain
-
-
?
topoisomerase-IIalpha + H2O
?
show the reaction diagram
-
-
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-L-Pro-L-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
preferred substrate for isoform CatL1G
-
-
?
trypsinogen + H2O
trypsin + ?
show the reaction diagram
-
cathepsin L inactivates human trypsinogen, CTSL-induced cleavage of trypsinogen occurs 3 amino acids toward the C-terminus from the cathepsin B activation site and results in a truncated, inactive form of trypsin and an elongated propeptide (trypsinogen activation peptide)
-
-
?
type 1 collagen + H2O
?
show the reaction diagram
-
efficient cleavage of type 1 collagen by isoform CatL5 is limited to the beta-and gamma-chains
-
-
?
type 1 collagen + H2O
?
show the reaction diagram
-
isoform Catl1G completely digests collagen type 1
-
-
?
Type I collagen + H2O
?
show the reaction diagram
-
-
-
-
?
Tyr-Gly-Gly-Phe-Leu + H2O
Tyr-Gly + Gly-Phe-Leu
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg + H2O
Tyr-Gly + Gly-Phe-Leu-Arg
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Leu-Arg-Arg
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile + H2O
Tyr-Gly + Gly-Phe-Leu-Arg-Arg-Ile
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Met + H2O
Tyr-Gly + Gly-Phe-Met
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Met-Arg-Arg
show the reaction diagram
-
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Arg + H2O
Tyr-Gly + Gly-Phe-Met-Arg-Arg
show the reaction diagram
-
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu + H2O
?
show the reaction diagram
-
cleavage sites Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Phe + H2O
?
show the reaction diagram
-
cleavage sites: Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-Arg-Phe-NH2 + H2O
?
show the reaction diagram
-
cleavage sites Gly-Gly and Met-Arg
-
-
?
Tyr-Gly-Gly-Phe-Met-NH2 + H2O
Tyr-Gly + Gly-Phe-Met-NH2
show the reaction diagram
-
-
-
-
?
Tyr-Gly-Gly-Phe-Met-NH2 + H2O
Tyr-Gly + Gly-Phe-Met-NH2
show the reaction diagram
-
-
-
?
vitronectin + H2
?
show the reaction diagram
Peptoclostridium difficile, Peptoclostridium difficile 79-685
Q83UF3
-
-
-
?
Z-Phe-Arg-7-amido-4-methyl-coumarin + H2O
?
show the reaction diagram
-
5 microM, pH 6.5, 28C
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amido-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Zaire Ebola virus glycoprotein + H2O
?
show the reaction diagram
-
-
three cleavage fragments with masses of 23000, 19000, and 4000 Da. Cleavage removes a glycosylated glycan cap and mucin-like domain (MUC domain) and exposes the conserved core residues implicated in receptor binding
-
?
methionine enkephalin-Arg-Phe + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
no activity with benzyloxycarbonyl-Phe-Ala-4-methylcoumarin 7-amide and with benzyloxycarbonyl-Phe-Met-4-methylcoumarin 7-amide
-
-
-
additional information
?
-
-
the enzyme removes the Ca-sensitivity of ATPase activity of myofibrils
-
-
-
additional information
?
-
-
the enzyme has a preference for hydrophobic amino acids in P2 and P3 residues
-
-
-
additional information
?
-
-
basement membrane of larval brains contains two substrate proteins
-
?
additional information
?
-
-
the enzyme is involved in tissue destruction in arthritis
-
-
-
additional information
?
-
-
involved in extracellular food digestion
-
-
-
additional information
?
-
-
the enzyme plays a most important role in intralysosomal proteolysis in hepatocytes
-
-
-
additional information
?
-
-
the enzyme plays a crucial role in the degradation of the invariant chain during maturation of major histocompatibility complex class II molecules and antigen processing
-
-
-
additional information
?
-
-
plays a crucial role in the pathogenesis of adjuvant arthritis
-
-
-
additional information
?
-
-
differentiation of human macrophages within the lung is accompanied by synthesis and expression of cathepsin L
-
-
-
additional information
?
-
-
enzyme activity plays a pivotal role in prolactin-induced spermatogonial apoptosis
-
?
additional information
?
-
-
p4165aa, a 65 amino acid segment of the p41 splice variant of major histocompatibility complex class II-associated invariant chain, stabilizes cathepsin L in the extracellular environment and induces a local decrease in the concentration of matrix-degrading enzymes during inflammation. Through its interaction with cathepsin L, complex class II-associated invariant chain Ii may control the migratory response of antigen-presenting cells and/or the recruitment of effectors of the inflammatory response
-
?
additional information
?
-
-
the enzyme is suggested to play a crucial role in the degradation of the basement membranes
-
?
additional information
?
-
P06797
upon interferon-gamma activation of peritoneal macrophages, enzymatic activityof cathepsin L is specifically inhibited, such that cathepsin S mediates Ii degradation and regulates MHC class II maturation
-
?
additional information
?
-
-
CAT L plays a significant role in numerous important physiological and pathological processes, such as bone resorption, cancer progression and atherosclerosis
-
-
-
additional information
?
-
-
cathepsin L elevates alpha-secretase activity, thereby suppressing amyloid precursor protein Abeta42 level. Cathepsin L reduces the formation of Abeta42 peptides by cleaving amyloid precursor protein within the Abeta peptide sequence. In addition, both cathepsins B and L degrade Abeta42 into less toxic Abeta peptides
-
-
-
additional information
?
-
-
cathepsin L expression levels regulate cell responsiveness to IGF-type I, function for cathepsin L in the control of the tumorigenic/metastatic phenotype
-
-
-
additional information
?
-
-
cathepsin L has a pro-survival function within the cell which may be due, at least in part, to its ability to deplete the cells from the proapoptotic molecule caspase-3. The existence of a proteolytic hierarchy between pro-survival and pro-death proteases suggests that changes in cellular proteolytic profiles are likely to have significant consequences not only on its survival but also on the type of death it may undergo in response to a specific stress
-
-
-
additional information
?
-
-
cathepsin L has a prominent role in the production of adrenocorticotropic hormone, beta-endorphin, and alpha-melanocyte stimulating hormone
-
-
-
additional information
?
-
-
catL is essential for epidermal homeostasis and regular hair follicle morphogenesis and cycling
-
-
-
additional information
?
-
-
contributions of cathepsin L and cathepsin B to autophagic protein degradation of cytoplasmic proteins in HeLa and Huh-7 cells are nearly equal. Cathepsin L does not play a general role in the degradation of proteins in the lumen of autophagosomes, but rather is involved specifically in the degradation of autophagosomal membrane markers
-
-
-
additional information
?
-
-
enzyme has a role in the progress of the cell cycle during the cleavage divisions of embryonic development. Inhibition of the protease abolishes the chromatin decondensation after mitosis
-
-
-
additional information
?
-
-
enzyme may involve in invasion of cercaria into fish and development to metacercaria, excystment of metacercaria, and protein digestion of adult
-
-
-
additional information
?
-
Q8IT42
granular amoebocytes immunopositive for cathepsin L are chemoattracted to the site of injury and phagocyte bacteria
-
-
-
additional information
?
-
-
pituitary gland may utilize the cathepsin L and prohormone convertase pathways for producing propiomelanocortin-derived peptide hormones
-
-
-
additional information
?
-
-
leucine is preferred over phenylalanine in position P2
-
-
-
additional information
?
-
A5HJW4
no activity towards benzyloxycarbonyl-Gly-Gly-L-Arg-7-amido-4-methylcoumarin
-
-
-
additional information
?
-
-
the cathepsin B and H specific synthetic substrates benzyloxycarbonyl-L-Ala-L-Ala-7-amido-4-trifluoromethylcoumarin and L-Arg-7-amido-4-methylcoumarin do not show any hydrolysis with the partially purified enzyme
-
-
-
additional information
?
-
-
the enzyme does not hydrolyze ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-KPVSTEQLAQ-N-[2,4-dinitrophenyl]ethylenediamine , Ortho-aminobenzoic acid-KPPVVLLPDQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine, ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine, and ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
-
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2
-
-
-
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2, isoform CatL1G is unable to digest albumin or hemoglobin, efficiently at either pH 5.5 or 7.0
-
-
-
additional information
?
-
Peptoclostridium difficile, Peptoclostridium difficile 79-685
Q83UF3
proteolytic activity only under reducing conditions, e.g. in presence of dithiothreitol. No substrate: type IV collagen
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
actomyosin + H2O
?
show the reaction diagram
-
endogenous cathepsin L of red bulleye surimi participates in gel disintegration during kamaboko processing by degrading the myosin heavy chain of actomyosin and consequently hindering the gelation of red bulleye surimi
-
-
?
Albumin + H2O
?
show the reaction diagram
-
isoform CatL5 shows weak activity against albumin
-
-
?
azocasein + H2O
?
show the reaction diagram
-
-
-
-
?
BAM-22P + H2O
(Met)enkephalin + ?
show the reaction diagram
-
-
-
-
?
casein + H2O
?
show the reaction diagram
-
-
-
-
?
Cholecystokinin + H2O
?
show the reaction diagram
-
-
-
-
?
chromogranin A + H2O
catestatin fragments + ?
show the reaction diagram
-
-
-
-
?
chromogranin A + H2O
catestatin
show the reaction diagram
-
-
-
-
?
collagen type IV + H2O
?
show the reaction diagram
-
-
-
-
?
collagen XVIII + H2O
endostatin + ?
show the reaction diagram
-
-
-
-
?
CUX1 transcription factor + H2O
?
show the reaction diagram
-
-
-
-
?
Disrupted in renal carcinoma 2 + H2O
?
show the reaction diagram
-
the substrate is proteolytically processed into a N-glycosylated N-terminal and a non-glycosylated C-terminal fragment, respectively. The cleavage site is between amino acid residues 214 and 261
-
-
?
E-cadherin + H2O
?
show the reaction diagram
-
-
-
-
?
Elastin + H2O
?
show the reaction diagram
-
-
-
-
?
endorepellin + H2O
anti-apoptotic C-terminal fragment of endorepellin + ?
show the reaction diagram
-
recombinant endorepellin is an in vitro substrate. Inhibition of cathepsin L activity in endothelial cells exposed to pro-apoptotic stimuli prevents release of anti-apoptotic C-terminal fragment of endorepellin without modulating the development of apoptosis. Inhibition of caspase-3 activation in endothelial cells concomitantly prevents cathepsin L release, production of anti-apoptotic C-terminal fragment of endorepellin, and the development of paracrine anti-apoptotic activity
-
-
?
Fibrinogen + H2O
?
show the reaction diagram
-
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
-
-
-
-
?
Fibronectin + H2O
?
show the reaction diagram
-
cleavage occurs only at pH 5.5
-
-
?
GABARAP-II protein + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
-
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
E5DHH4
-
-
-
?
Gelatin + H2O
?
show the reaction diagram
A5HJW4
on gelatin-zymography, the purified pro-mature enzyme of cathepsin L is capable of hydrolyzing 0.1% gelatin at pH 7.5
-
-
?
histone H1 + H2O
?
show the reaction diagram
-
-
-
-
?
histone H3 + H2O
?
show the reaction diagram
-
-
-
-
?
histone H3 + H2O
?
show the reaction diagram
-
during embryonic stem cell differentiation, histone H3 is proteolytically cleaved at its N-terminus. H3 cleavage may be regulated by covalent modifications present on the histone tail itself
-
-
?
Immunoglobulin + H2O
?
show the reaction diagram
-
-
-
-
?
interleukin-8 precursor + H2O
?
show the reaction diagram
-
enzyme plays an important role in IL-8 processing in inflammatory sites
-
?
Kininogen + H2O
Kinin
show the reaction diagram
-
high and low molecular weight kininogen
-
?
Laminin + H2O
?
show the reaction diagram
-
-
-
-
?
Laminin + H2O
?
show the reaction diagram
-
cleavage occurs only at pH 5.5
-
-
?
Nipah virus fusion protein + H2O
?
show the reaction diagram
-
proteolytically processed within endosomes by cathepsin L
-
-
?
perforin + H2O
?
show the reaction diagram
-
CatL preferentially cleaves a site on full-length recombinant perforin close to its C terminus
-
-
?
pro-dipeptidyl peptidase I
?
show the reaction diagram
-
cathepsin L could be an important activator of dipeptidyl peptidase I in vivo
-
?
pro-dynorphin + H2O
?
show the reaction diagram
-
-
-
-
?
pro-enkephalin + H2O
enkephalin + ?
show the reaction diagram
-
-
-
-
?
Pro-opiomelanocortin + H2O
?
show the reaction diagram
-
-
-
-
?
pro-urokinase plasminogen activator + H2O
?
show the reaction diagram
-
-
-
-
?
proheparanase + H2O
active form of heparanase + ?
show the reaction diagram
-
removal of the linker peptide and conversion of proheparanase into its active 8 + 50-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
proheparanase + H2O
active form of heparanase + ?
show the reaction diagram
-
removal of the linker peptide and conversion of proheparanase into its active 850-kDa form is brought about predominantly by cathepsin L. Excision of a 10-amino acid peptide located at the C terminus of the linker segment between two functional cathepsin L cleavage sites at Y156Q and Y146Q is critical for activation of proheparanase. The entire linker segment of proheparanase is susceptible to multiple endocleavages by cathepsin L, generating small peptides. Processing and activation of proheparanase can be brought about solely by cathepsin L
-
-
?
secretory leukocyte protease inhibitor + H2O
?
show the reaction diagram
-
incubation of recombinant secretory leukocyte protease inhibitor with cathepsin L leads to complete loss of activity while encapsulation of recombinant secretory leukocyte protease inhibitor in 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine]-cholesterol liposomes retains 92.6% of its activity after challenge with cathepsin L
-
-
?
topoisomerase-IIalpha + H2O
?
show the reaction diagram
-
-
-
-
?
trypsinogen + H2O
trypsin + ?
show the reaction diagram
-
cathepsin L inactivates human trypsinogen, CTSL-induced cleavage of trypsinogen occurs 3 amino acids toward the C-terminus from the cathepsin B activation site and results in a truncated, inactive form of trypsin and an elongated propeptide (trypsinogen activation peptide)
-
-
?
type 1 collagen + H2O
?
show the reaction diagram
-
efficient cleavage of type 1 collagen by isoform CatL5 is limited to the beta-and gamma-chains
-
-
?
type 1 collagen + H2O
?
show the reaction diagram
-
isoform Catl1G completely digests collagen type 1
-
-
?
Z-Phe-Arg-7-amido-4-methylcoumarin + H2O
Z-Phe-Arg + 7-amido-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
Zaire Ebola virus glycoprotein + H2O
?
show the reaction diagram
-
-
three cleavage fragments with masses of 23000, 19000, and 4000 Da. Cleavage removes a glycosylated glycan cap and mucin-like domain (MUC domain) and exposes the conserved core residues implicated in receptor binding
-
?
LC3-II protein + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
the enzyme is involved in tissue destruction in arthritis
-
-
-
additional information
?
-
-
involved in extracellular food digestion
-
-
-
additional information
?
-
-
the enzyme plays a most important role in intralysosomal proteolysis in hepatocytes
-
-
-
additional information
?
-
-
the enzyme plays a crucial role in the degradation of the invariant chain during maturation of major histocompatibility complex class II molecules and antigen processing
-
-
-
additional information
?
-
-
plays a crucial role in the pathogenesis of adjuvant arthritis
-
-
-
additional information
?
-
-
differentiation of human macrophages within the lung is accompanied by synthesis and expression of cathepsin L
-
-
-
additional information
?
-
-
enzyme activity plays a pivotal role in prolactin-induced spermatogonial apoptosis
-
?
additional information
?
-
-
p4165aa, a 65 amino acid segment of the p41 splice variant of major histocompatibility complex class II-associated invariant chain, stabilizes cathepsin L in the extracellular environment and induces a local decrease in the concentration of matrix-degrading enzymes during inflammation. Through its interaction with cathepsin L, complex class II-associated invariant chain Ii may control the migratory response of antigen-presenting cells and/or the recruitment of effectors of the inflammatory response
-
?
additional information
?
-
-
the enzyme is suggested to play a crucial role in the degradation of the basement membranes
-
?
additional information
?
-
P06797
upon interferon-gamma activation of peritoneal macrophages, enzymatic activityof cathepsin L is specifically inhibited, such that cathepsin S mediates Ii degradation and regulates MHC class II maturation
-
?
additional information
?
-
-
CAT L plays a significant role in numerous important physiological and pathological processes, such as bone resorption, cancer progression and atherosclerosis
-
-
-
additional information
?
-
-
cathepsin L elevates alpha-secretase activity, thereby suppressing amyloid precursor protein Abeta42 level. Cathepsin L reduces the formation of Abeta42 peptides by cleaving amyloid precursor protein within the Abeta peptide sequence. In addition, both cathepsins B and L degrade Abeta42 into less toxic Abeta peptides
-
-
-
additional information
?
-
-
cathepsin L expression levels regulate cell responsiveness to IGF-type I, function for cathepsin L in the control of the tumorigenic/metastatic phenotype
-
-
-
additional information
?
-
-
cathepsin L has a pro-survival function within the cell which may be due, at least in part, to its ability to deplete the cells from the proapoptotic molecule caspase-3. The existence of a proteolytic hierarchy between pro-survival and pro-death proteases suggests that changes in cellular proteolytic profiles are likely to have significant consequences not only on its survival but also on the type of death it may undergo in response to a specific stress
-
-
-
additional information
?
-
-
cathepsin L has a prominent role in the production of adrenocorticotropic hormone, beta-endorphin, and alpha-melanocyte stimulating hormone
-
-
-
additional information
?
-
-
catL is essential for epidermal homeostasis and regular hair follicle morphogenesis and cycling
-
-
-
additional information
?
-
-
contributions of cathepsin L and cathepsin B to autophagic protein degradation of cytoplasmic proteins in HeLa and Huh-7 cells are nearly equal. Cathepsin L does not play a general role in the degradation of proteins in the lumen of autophagosomes, but rather is involved specifically in the degradation of autophagosomal membrane markers
-
-
-
additional information
?
-
-
enzyme has a role in the progress of the cell cycle during the cleavage divisions of embryonic development. Inhibition of the protease abolishes the chromatin decondensation after mitosis
-
-
-
additional information
?
-
-
enzyme may involve in invasion of cercaria into fish and development to metacercaria, excystment of metacercaria, and protein digestion of adult
-
-
-
additional information
?
-
Q8IT42
granular amoebocytes immunopositive for cathepsin L are chemoattracted to the site of injury and phagocyte bacteria
-
-
-
additional information
?
-
-
pituitary gland may utilize the cathepsin L and prohormone convertase pathways for producing propiomelanocortin-derived peptide hormones
-
-
-
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2
-
-
-
additional information
?
-
-
isoform CatL1G can cleave substrates with proline residues at P2, isoform CatL1G is unable to digest albumin or hemoglobin, efficiently at either pH 5.5 or 7.0
-
-
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Ca2+
A5HJW4
202.43% relative activity at 1 mM
K+
A5HJW4
141.16% relative activity at 1 mM
Mg2+
A5HJW4
295.3% relative activity at 5 mM
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(((2S,3S)-epoxysuccinyl-(S)-leucyl)amino)-4-guanidinobutane
-
-
(2E)-2-(7-bromo-3,4-dihydronaphthalen-1(2H)-ylidene)hydrazinecarbothioamide
-
-
(2E)-2-[(2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,4,5-trifluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-dichlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[3-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[[3,5-bis(trifluoromethyl)phenyl](3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2R,3R)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-3-([(2S)-1-[(8-carbamimidamidooctyl)amino]-4-methyl-1-oxopentan-2-yl]carbamoyl)oxirane-2-carboxylic acid
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(R)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(S)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[biotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R+S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-pipecolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
i.e. CAA0225. Significantly inhibits degradation of long-lived proteins in HeLa and Huh-7 cells cultured under nutrient-deprived conditions. CAA0225 effectively inhibits degradation of microtubule-associated protein IA/IB light chain 3-II and gamma-aminobutyric acid (A) receptor-associated protein
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
i.e. CAA0225. IC50 value for rat liver cathepsin B above 1 microM
(2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester
Q6UB44
0.1 mM
(2S,3S+2R,3R)-dibenzyl-1-[desthiobiotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2Z)-2-[(2-bromophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-fluorophenyl)(phenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-2-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-4-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3,4,5-tetrafluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,6-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(4-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[[3,5-bis(trifluoromethyl)phenyl](4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
(E)N-[(S)1-[(S)2-cyano-1-pyrrolidinecarbonyl]-3-methylbutyl]-2,3-diphenylacrylamide
-
selective towards cathepsin L over cathepsin B
(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucine(3-methylbutyl)-amide
-
0.01 mg/ml
(R)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
-
R-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
(S)-2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarboxylate
-
-
(S)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
-
S-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
1,10-phenanthroline
-
-
1,10-phenanthroline
A5HJW4
36.6% inhibition at 0.1 mM
1,3-dihydro-pyrrolo[3,4-b]quinoline-2-carbonitrile
-
IC50: 0.00045 mM
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([2-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-3-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-4-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(thiophen-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[methyl(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(methylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(phenylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-([[4-([[(dimethylamino)methyl]sulfonyl]amino)phenyl]carbonyl]amino)-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([2-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-fluoro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([4-[(ethylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-(methylsulfamoyl)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-([[4-(1-methylethyl)-1,3-thiazol-2-yl]sulfonyl]amino)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-sulfamoylphenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methyl-1H-imidazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methylethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2-methylphenyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methylpyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(5-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[4-methyl-N-(thiophen-3-ylcarbonyl)-L-leucyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(benzylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(butylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(cyclopropylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-chloropyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(3-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(4-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(cyclohexylmethyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1- (L-trans-epoxysuccinyl-leucylamino)-4-guanidinobutane
-
i.e. E-64, 0.1 mM, complete loss of activity
1-cyano-3-azetidinyl cyclohexylmethyl ether
-
IC50: 0.00001 mM
1-cyanoazetidine
-
IC50: 0.00043 mM
1-cyanopyrrolidine
-
IC50: 0.004 mM
1-naphthalenesulfonyl-Ile-Trp-aldehyde
-
cathepsin L inhibitor
1-naphthalenesulfonyl-Ile-Trp-aldehyde
-
selective intra- and extracellular cathepsin L inhibitor
1-nathalenesulfonyl-Ile-Trp-CHO
-
treatment of cells results in suppression of cellular proliferation and the induction of a cell death with no detecable caspase-3 activation or DNA fragmentation. Cell death is associated with increased accumulation of cathepsin D, cellular vacuolization, expression of the mannose 6-phosphate recepto, and the autophagy marker LC-II
2,3,7,8-tetrachlorodibenzodioxin
-
treatment of cells results in resistance to apoptosis, increased expression of the tumor marker cathepsin L, and a high degree of invasiveness
2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylate
-
unreactive to transesterification by cysteine and dithiothreitol nucleophiles. Inhibitor remains intact for greater than 24 h when incubated with cathepsin L under stoichiometric conditions, and in the presence of assay buffer
2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-(cyclohexylmethoxy)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
-
2-cyano-4-[(2-cyclopentylethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
-
2-cyano-4-[(6,8-dioxaspiro[3.5]non-7-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
-
2-cyano-4-[(cyclohexylmethyl)(methyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-[(cyclohexylmethyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-N-(2-phenylethyl)-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-4-[[(4,4-difluorocyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-[[(4,4-dimethylcyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
-
2-cyano-4-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-(1-methyl-4-phenylpiperidin-4-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-(2-phenylethyl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-(4,5-dimethoxybiphenyl-2-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[4.5]dec-8-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[(spiro[3.5]non-7-ylmethyl)amino]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-methyl-4-[[1-(1-methylethyl)piperidin-4-yl]methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-[(1-methyl-4-phenylpiperidin-4-yl)methyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-[(1R)-2-pyridin-2-yl-1-(pyrrolidin-1-ylmethyl)ethyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-cyano-N-[5-[(1-methylpiperidin-4-yl)oxy]biphenyl-2-yl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
2-furancarbonyl-leucyl-leucyl-leucinal
-
-
2-mercaptoethanol
-
50% activity at 2 mM
2-[bis(3-bromophenyl)methylidene]-N-ethylhydrazinecarbothioamide
-
-
2-[bis(3-bromophenyl)methylidene]-N-phenylhydrazinecarbothioamide
-
-
2-[bis(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[cyclohexyl(methyl)amino]-4H-3,1-benzothiazin-4-one
-
selective towards cathepsin L over cathepsin G, chymotrypsin, trypsin, human angiotensin-converting enzyme, human leukocyte elastase, acetylcholinesterase
2RS,3RS)-2-benzyl-3-ethyl-1-[N-(benzyloxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
3-(benzyloxy)-1-cyanoazetidine
-
IC50: 0.00001 mM
3-chloro-N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
3-[(benzyloxy)methyl]-1-cyanopyrrolidine
-
IC50: 0.00015 mM
3-[[(2S)-2-[([3-acetyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[(2S)-2-[[(4-[[(4-aminophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4-[(1-acetylpiperidin-4-yl)methoxy]-2-cyano-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
-
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzoic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
-
5-bromo-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
-
6-(4-chlorobenzyl)-7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclooctylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-piperidin-1-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3,3-dimethylbutyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3-cyclohexylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(4,4-dimethylpentyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(3-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-[[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(1-acetylpiperidin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(4-acetyl-1,4-diazepan-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)-3-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
7-(2-cyclohexylethyl)-6-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(phenoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(phenylamino)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-yloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-ylsulfanyl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[[methyl(phenyl)amino]methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
acetyl-Leu-Leu-Tyr-CHN2
-
-
acetyl-prolyl-leucyl-leucyl-leucinal
-
-
acetyl-prolyl-prolyl-leucyl-leucyl-leucinal
-
-
alpha2 cysteine-proteinase inhibitor
-
-
-
antipain
-
-
antipain
-
-
antipain
-
1 mM, complete loss of activity
antipain
A5HJW4
97.26% inhibition at 0.1 mM
Aprotinin
A5HJW4
55.22% inhibition at 0.1 mM
azepanone
-
-
Azodicarboxylic acid alpha-morpholide
-
-
-
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-naphthylen-2-yl)amide
-
-
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenyl-ethyl)amide
-
-
benzyl 1-cyano-3-pyrrolidinylcarbamate
-
IC50: 0.000054 mM
benzyloxycarbonyl-FF-fluoromethylketone
-
cathepsin L-specific inhibitor
benzyloxycarbonyl-iodophenylalanine-Ala-CHN2
-
-
benzyloxycarbonyl-iodotyrosine-Ala-CHN2
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
-
irreversible and selective inhibitor of cathepsin L
benzyloxycarbonyl-Leu-homophenylalanine-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Phe-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-Leu-Met-CHN2
-
-
benzyloxycarbonyl-Leu-Trp-CHN2
-
-
benzyloxycarbonyl-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-leucyl-leucyl-leucinal
-
-
Benzyloxycarbonyl-Phe-Ala-CHN2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
-
-
benzyloxycarbonyl-Phe-Phe fluoromethylketone
-
cell-permeable irreversible cathepsin inhibitor
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
Benzyloxycarbonyl-Phe-Phe-CHN2
-
-
benzyloxycarbonyl-Phe-Phe-fluoromethyl ketone
-
-
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
-
irreversible cathepsin L inhibitor
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
-
-
benzyloxycarbonyl-Phe-Tyr-CHO
-
-
benzyloxycarbonyl-Phe-X-CHN2
-
-
-
benzyloxycarbonyl-PheTyr-[tert-butyl]-diazomethylketone
-
specific inhibitor
benzyloxycarbonyl-Tyr-Ala-CHN2
-
-
biphenyl-4-yl-acetylasparagine-D-Arg-Phe-Phe-NH2
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Abu-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Arg-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-Phe-NH2
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Trp-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylcysteine-D-Arg-Tyr-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Leu-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Met-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
the inhibitor shows a 310fold and 210fold selectivity for cathepsin L over cathepsin K and B, respectively
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(3-phenylpropyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(benzyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-Phe-NH2
-
-
biphenyl-4-yl-acetylmethylcysteine-D-Orn-Phe-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylmethylcysteine-Gly-Phe-Phe-NH2
-
-
biphenyl-4-yl-acetylnorvaline-D-Arg-Phe-N-(2-phenylethyl)amide
-
-
biphenyl-4-yl-acetylserine-D-Arg-Phe-Phe-NH2
-
-
biphenylacetyl-(N6-biphenylacetyl)-Lys-D-Arg-Tyr-N-phenylethyl
-
-
biphenylacetyl-(N6-biphenylacetyl)Lys-D-Arg-Phe-N-phenylethyl
-
-
biphenylacetyl-MCys-D-Arg-Phe-N-phenylethyl
-
-
CA-074Me
-
0.01 mM
CA-074Me
-
in cells transfected with Nipah virus fusion protein, treatment with inhibitor CA-074ME almost completely prevents proteolytic processing of F0 into F1 and F2
CA-074Me
-
-
CA-074Me
-
cathepsin L activity is suppressed by 0.04 mM CA-074Me in NIH-3T3 cells
CA-074Me
-
-
CA-074Me
-
-
Ca2+
-
51% residual activity at 1 mM
CAA0225
-
i.e. (2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide]3-[[2-(4-hydroxy-phenyl)-ethyl]-amide], a cathepsin L-specific inhibitor
Calpeptin
-
0.01 mM
cathepsin K propeptide
-
-
-
cathepsin L inhibitor 1
-
-
cathepsin L inhibitor I
-
0.05 mM
cathepsin L inhibitor III
-
0.01 mM
cathepsin L propeptide
-
-
-
cathepsin S propeptide
-
-
-
chagasin
-
-
-
chagasin mutant delta T31-T32
-
-
-
chagasin mutant P30A
-
-
-
chagasin mutant T31A
-
-
-
chagasin mutant T31A/T32A
-
-
-
chagasin mutant T31S
-
-
-
chagasin mutant T31V
-
-
-
chagasin mutant T31Y
-
-
-
chagasin mutant T32A
-
-
-
chagasin mutant T32S
-
-
-
chagasin mutant T32V
-
-
-
chagasin mutant T32Y
-
-
-
chagasin mutant W93A
-
-
-
Chloroquine
-
chloroquine inhibits the infection with live Nipah virus and Hendra virus at a concentration of 1 microM in vitro. The mechanism for the antiviral action likely is the inhibition of cathepsin L, which is essential for the processing of the viral fusion glycoprotein and the maturation of newly budding virions
chymostatin
-
-
chymostatin
-
-
chymostatin
A5HJW4
21.29% inhibition at 0.1 mM
chymostatin
-
32.24% residual activity at 0.2 mM
CID 16725315
-
2% inhibition at 0.025 mM
CID 23631927
-
38% inhibition at 0.025 mM, sub-nanomolar slow-binding, reversible inhibitor of human cathepsin L with cathepsin L/B selectivity of above 700fold that blocks SARS-CoV and Ebola pseudotype virus entry in human cells
CLICK148
-
-
CLIK-148
-
treatment of AtT-20 cells results in reduced production of adrenocorticotropic hormone and accumulation of proopiomelanocortin
CLIK-148
-
-
CLIK-148
-
specific cathepsin L inhibitor
CLIK-148
-
specific inhibitor of cathepsin L
CLIK148
Q6UB44
0.1 mM
CLIK148
-
complete inhibition at 0.01 mM
CLIK148
-
cathepsin L-specific inhibitor
CLIK148
-
cathepsin L-specific inhibitor, CLIK148 attenuates Eco-MLV infection in NIH3T3 cells
CLIK148
-
cathepsin L-specific inhibitor
CLIK195
-
complete inhibition at 0.01 mM
Co2+
-
complete inhibition at 1 mM
Co2+
A5HJW4
8.01% residual activity at 5 mM
CoCl2
-
partial
Cu2+
-
complete inhibition at 1 mM
Cu2+
-
1 mM, 19% residual activity
Cu2+
A5HJW4
complete inhibition at 5 mM
Cystatin
-
-
-
Cystatin
-
important role of Gly4 in the binding to the enzyme
-
Cystatin
-
from chicken, activity with benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
cystatin A
-
-
-
cystatin A
-
-
-
cystatin alpha
-
0.05 mg/ml
-
cystatin B
-
-
-
cystatin B
-
-
-
cystatin B
-
cystatin B (stefin B) plays an important role in regulating the proteolytic activity of cathepsin L in the nucleus by protecting the CUX1 transcription factor and probably other substrates from proteolytic cleavage by cathepsin L
-
cystatin C
-
-
-
cystatin C
-
-
-
cystatin D
-
-
-
cystatin D
-
-
-
cystatin E/M
-
-
-
cystatin F
-
-
-
cystatin F
-
-
-
cystatin M/E
-
-
-
cystatin SA
-
-
-
cystatin SN
-
-
-
diazinedicarboxylic acid bismethylamide
-
-
-
diazomethanes
-
irreversible inhibition of hydrolysis of leucine enkephalin
-
diethyl-cyanamide
-
IC50 is above 0.1 mM
dithiothreitol
-
-
E-64
-
activity with benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
E-64
-
complete inhibition at 0.1 mM
E-64
-
irreversible inhibitor
E-64
-
0.01 mM
E-64
A5HJW4
i.e. transepoxysuccinyl-L-leucyl-amido(4-guanidino) butane, 60.1% inhibition at 0.5 mM
E-64
-
i.e. L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane, 24.76% residual activity at 1 mg/ml
E-64
-
i.e. L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane
E-64
-
broad-spectrum cathepsin inhibitor, cathepsin L irreversible binding
E-64
E5DHH4
99.7% inhibition at 0.01 mM
E-64d
-
in cells transfected with Nipah virus fusion protein, treatment with inhibitor E-64d almost completely prevents proteolytic processing of F0 into F1 and F2
E-64d
-
-
E64
-
0.1 mM, complete inhibition
EDTA
-
98% residual activity at 2 mM
EDTA
A5HJW4
10.81% inhibition at 0.1 mM
EDTA
-
5 mM, 81% residual activity
EGTA
A5HJW4
40.55% inhibition at 0.1 mM
endopin 2
-
enodgenous inhibitor, present in pituitary gland
-
endopin 2
-
endogenous protease inhibitor. High level of co-localization with enkephalin and NPY neuropeptides present in secretory vesicles of adrenal medullary chriomaffin cells in primary culture. Expression in brain, pituitary, adrenal medulla, and other neuroendocrine tissues
-
endopin 2C
-
endopin 2C inactivaties cathepsin L by binding to the enzyme, after dissociation from cathepsin L its activity is recovered within 60 min
-
Ep-460
-
-
Ep-475
-
-
Ep-475
-
cathepsin L irreversible binding
ethanesulfonothioate
-
-
Fe2+
-
5% residual activity at 1 mM
Fe3+
-
complete inhibition at 1 mM
Flufenamic acid
-
-
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
inhibitory to human cathepsin V, cathepsin L, cathepsin K, cathepsin F with Ki values in the low nanomolar range. Ki values are sufficiently low to ensure complex formation at physiological concentrations. Regulation of the proteolytic activity of most of the cysteine cathepsins by the p41 fragment is an important and widespread control mechanism of antigen presentation
-
glucose
-
high concentrations
gossypol
-
-
Hg2+
-
HgCl2; weak
Hg2+
-
HgCl2
Hg2+
-
HgCl2
Hg2+
A5HJW4
37.32% residual activity at 1 mM
HgCl2
-
-
indomethacin
-
-
iodoacetamide
-
-
iodoacetamide
-
-
iodoacetate
-
complete inhibition at 1 mM
iodoacetic acid
-
-
iodoacetic acid
-
-
iodoacetic acid
-
strong
iodoacetic acid
-
-
iodoacetic acid
-
-
iodoacetic acid
-
-
iodoacetic acid
-
1 mM, complete loss of activity
iodoacetic acid
-
10 mM, 15% residual activity
isonicotinyl-leucyl-leucyl-leucinal
-
-
JPM-565
-
cathepsin L irreversible binding
JPM-OEt
-
cathepsin L irreversible binding
KAPR-acetyl-K-QLATKAARKSAPA
-
-
-
KAPRKQLAT-acetyl-K-AARKSAPA
-
-
-
KAPRKQLATKAAR-dimethyl-K-SAPA
-
-
-
KAPRKQLATKAARKSAPA
-
-
-
kininogen domain 3
-
-
-
L-1-tosyl-2-phenylethylchloromethylketone
-
-
L-3-carboxy-trans-2,3-epoxypropionyl-leucylamido-(3-methyl)butane
-
-
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
the susceptibility of recombinant enzyme to substrate inhibition at 25C is partially reversible, i.e., it is absent at 37C and is displayed when the same enzyme sample is assayed again at 25C
L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane
-
complete inhibition at 0.1 mM
L-trans-epoxysuccinyl-leucylamido(3-methyl)butane
-
-
L-trans-epoxysuccinyl-leucylamido-(4-guanidino)butane
-
E-64
L-trans-epoxysuccinylleucylamido-(4-guanidino)butane
-
i.e. E-64, complete inhibition at 0.26 mM
Leu-CH2Cl
-
-
Leu-Leu-Tyr-CHN2
-
-
Leupeptin
-
-
Leupeptin
-
reversible inhibition of hydrolysis of leucine enkephalin
Leupeptin
-
-
Leupeptin
-
-
Leupeptin
-
-
Leupeptin
-
pseudo-irreversible inhibitor
Leupeptin
-
-
Leupeptin
-
-
Leupeptin
-
-
Leupeptin
-
0.1 mg/ml
Leupeptin
-
complete inhibition at 0.1 mM
Leupeptin
-
1 mM, 31% residual activity
Leupeptin
A5HJW4
95.85% inhibition at 0.1 mM
Leupeptin
-
11.06% residual activity at 0.001 mg/ml
Leupeptin
-
-
Leupeptin
-
0.1 mM, less than 10% residual activity
LFLRL
-
0.05 mM, 78% inhibition
LFLTR-NH2
-
IC50: 0.0008 mM
LKFTF
-
0.05 mM, 24% inhibition; 0.05 mM, 32% inhibition
LKFTR
-
0.05 mM, 78% inhibition
LKLFF
-
0.05 mM, 42% inhibition
LKLFW
-
0.05 mM, 22% inhibition
LKLLW
-
0.05 mM, 75% inhibition
LLFLW
-
0.05 mM, 52% inhibition
LLFRW
-
0.05 mM, 52% inhibition
LLLLR
-
0.05 mM, 62% inhibition
LLLLW
-
0.05 mM, 37% inhibition
LLLRW
-
0.05 mM, 83% inhibition
LLLTB
-
0.05 mM, 58% inhibition
LLLTL
-
0.05 mM, 67% inhibition
LLLTR-NH2
-
IC50: 0.0005 mM
LLLTW
-
0.05 mM, 62% inhibition
LLYLW
-
0.05 mM, 47% inhibition
LLYTB
-
0.05 mM, 25% inhibition
LLYTR
-
0.05 mM, 62% inhibition
LLYTW
-
0.05 mM, 30% inhibition
low-MW cysteine proteinase inhibitor
-
-
-
LRFTF
-
0.05 mM, 25% inhibition
LRLLW
-
0.05 mM, 73% inhibition
LWFFW
-
0.05 mM, 61% inhibition
LWFRQ
-
0.05 mM, 20% inhibition
LWFRW
-
0.05 mM, 20% inhibition
LWLFL
-
0.05 mM, 73% inhibition
LWLFW
-
0.05 mM, 31% inhibition
LWLLW
-
0.05 mM, 52% inhibition
MDL28170
-
-
MENT
-
potent and very specific irreversible cathepsin L inhibitor
-
Mersalyl acid
-
-
methyl 5-acetyloxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methyl 5-hydroxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methylphenylazoformate
-
-
MG-132
-
0.001 mM
Mg2+
-
66% residual activity at 1 mM
morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl
Q6DMN0
moderate inhibitor
morpholinylsuccinyl-leucyl-leucyl-leucinal
-
-
N-(1-cyano-3-pyrrolidinyl)benzamide
-
IC50: 0.00175 mM
N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide
-
IC50: 0.00008 mM
N-(1-cyano-3-pyrrolidinyl)[1,1'-biphenyl]-4-carboxamide
-
IC50: 0.00085 mM
N-(1-cyanopyrrolidin-3-yl)benzenesulfonamide
-
-
N-(4-benzyl-1-methylpiperidin-4-yl)-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-(4-biphenylacetyl)-S-methylcysteine-(D)-Arg-Phe-beta-phenethylamide
-
also called Cat L inhibitor 7, specific inhibitor
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)propanamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)oxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-benzyl-2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-benzyl-2-[bis(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
N-benzyloxycarbonyl-Phe-Phe-fluoromethylketone
-
-
N-ethylmaleimide
-
10 mM, less than 10% residual activity
N-[(1-cyano-2-pyrrolidinyl)methyl]benzamide
-
IC50: 0.023 mM
N-[(1-cyano-2-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.0115 mM
N-[(1-cyano-3-azetidinyl)methyl]benzamide
-
IC50: 0.00065 mM
N-[(1-cyano-3-azetidinyl)methyl]benzenesulfonamide
-
IC50: 0.00005 mM
N-[(1-cyano-3-azetidinyl)methyl]cyclohexanecarboxamide
-
IC50: 0.000006 mM
N-[(1-cyano-3-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.00035 mM
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylpropyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-[(1S)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
-
N-[(2S)-1-(1H-indol-3-yl)-3-oxopropan-2-yl]-N2-(naphthalen-1-ylsulfonyl)-L-isoleucinamide
-
-
N-[(2S)-1-(3-chlorophenyl)-3-[(cyanomethyl)amino]but-3-en-2-yl]benzamide
-
-
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1-methyl-3-(propan-2-yl)-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,3-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethyl-1,3-oxazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylthiophene-3-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,7-dimethylnaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-4-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-5,6,7,8-tetrahydronaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cycloheptanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohex-1-ene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohexanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]naphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]quinoline-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-4-methyl-1-oxo-1-[[(4S)-3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-yl]amino]pentan-2-yl]-1-benzofuran-2-carboxamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(3S)-1-cyanopyrrolidin-3-yl]-L-leucinamide
-
-
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-3-chloro-N-(cyanomethyl)-L-phenylalaninamide
-
pH and temperature not specified in the publication
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-N-(cyanomethyl)-3-methyl-L-phenylalaninamide
-
pH and temperature not specified in the publication
naphthalene-2-carboxylic acid ((S)-2-naphthalen-2-yl-1-[(S)-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]ethyl)amide
-
-
naphthoic-1-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
NEM
A5HJW4
40.84% inhibition at 0.1 mM
Ni2+
-
complete inhibition at 1 mM
nicotinyl-leucyl-leucyl-leucinal
-
-
OC-1DELTAD86
-
0.002 mM
-
ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine
-
efficient cathepsin L inhibitor
ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
p-21s
-
c-Ha-ras gene product
-
p-21s
-
c-Ha-ras proteins produced by Escherichia coli potent inhibitor
-
p-hydroxymercuribenzoate
-
-
p41 fragment
-
-
-
p41-fragment-human
-
64 residues present in the p41 form of the human major histocompatibility complex II (MHCII)-associated invariant chain
-
p41-fragment-mouse
-
64 residues present in the p41 form of the murine major histocompatibility complex II (MHCII)-associated invariant chain
-
P41icf
-
synthesis and NMR structure of the potent inhibitor
-
pefabloc
-
78.43% residual activity at 2 mg/ml
Pepstatin
-
58.06% residual activity at 0.001 mg/ml
Pepstatin
-
0.01 mM, 90% residual activity
pepstatin A
A5HJW4
21.54% inhibition at 0.1 mM
Phe-Tyr-(OBut)-COCHO
-
potent, reversible, synthetic peptidyl inhibitor of cathepsin L
-
Phe-Tyr-(tert-Bu)-diazomethylketone
-
irreversible inhibitor that can inactivate cathepsin L at micromolar concentrations
-
Phenylbutazone
-
noncompetitive inhibitor
phenylmethanesulfonyl fluoride
-
-
phenylmethylsulfonyl fluoride
A5HJW4
10.6% inhibition at 0.1 mM
phenylmethylsulfonyl fluoride
-
10 mM, less than 10% residual activity
propeptide
-
-
-
Protein C inhibitor
-
inhibits cathepsin L with an inhibition rate (k2) of 30000 0 M-1 s-1
-
quinoline-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
quinoline-8-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
RFLRW
-
0.05 mM, 21% inhibition
RFLYR
-
0.05 mM, 64% inhibition
RKLFL
-
0.05 mM, 79% inhibition
RKLLW-NH2
-
IC50: 0.0006 mM
RKLWD-NH2
-
IC50: 0.014 mM
RKLWF
-
0.05 mM, 52% inhibition
RKLWL-NH2
-
IC50: 0.0008 mM
RKLWV
-
0.05 mM, 41% inhibition
RLLLW
-
0.05 mM, 75% inhibition
RLLYW
-
0.05 mM, 29% inhibition
RRFYV
-
0.05 mM, 24% inhibition
RRLTW
-
0.05 mM, 38% inhibition
RRYLB
-
0.05 mM, 33% inhibition
RWLTL
-
0.05 mM, 61% inhibition
RWLYL
-
0.05 mM, 65% inhibition
S-(2-oxo-1-phenylpyrrolidin-3-yl) 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
slow binding and slowly reversible inhibitor. 7- to 151fold greater selectivity towards cathepsin L then papain and cathepsins B, K, V, and S with no activity against cathepsin G. Inhibitor lacks toxicitiy in human aortic endothelial cells and inhibits in vitro propagation of Plasmodium falciparum with an IC50 value of 15.4 microM and of Leishmania major with an IC50 value of 12.5 microM
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
CID16725315, slowly reversible inhibition
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]hydrazinecarbothioate
-
-
salicylic acid
-
and its m-analogs and p-analogs
serpin B3
-
about 35% inhibition at 7.5 nM, the presence of heparin accelerates inhibition of cathepsin L by serpin B3 (4.1fold increase in rate of inhibition)
-
serpin B4
-
about 70% inhibition at 100 nM, the presence of 50 nM heparin accelerates inhibition of cathepsin L by serpin B4 (4.1fold increase in rate of inhibition)
-
SnCl2 <
-
partial
Soybean trypsin inhibitor
-
63.12% residual activity at 0.05 mg/ml
-
Stefin A
-
-
-
tert-butyloxycarbonyl-Lys(epsilon-9-fluorenylmethoxycarbonyl)-Leu-Tyr-CHN2
-
-
-
tert-butyloxycarbonyl-Lys-Leu-Tyr-CHN2
-
-
-
tert-butyloxycarbonyl-Val-Lys(epsilon-benzyloxycarbonyl)-Leu-Tyr-CHN2
-
-
testican-1
-
strong competitive inhibitor, inhibition is independent of its chondroitin sulfate chains and is effective at both pH 5.5 and pH 7.2, does not inhibit the structurally related lysosomal cysteine protease cathepsin B
-
Tg1 domain of testican-1
-
-
-
thyroglobulin type-1 domain
-
-
-
TLCK
-
10 mM, less than 10% residual activity
tosyl phenylalanyl chloromethylketone
-
66.63% residual activity at 0.1 mg/ml
tosyl-Lys-CH2Cl
-
-
tosyl-Lys-CH2Cl
-
-
tosyl-Lys-CH2Cl
-
-
tosyl-Lys-CH2Cl
-
-
tosyl-Lys-CH2Cl
-
-
tosyl-Phe-CH2Cl
-
-
tosyl-Phe-CH2Cl
-
-
toxostatin
-
endogenous inhibitor, acts both on cathepsin L and cathepsin B in the nanomolar range
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
i.e. E-64, in vivo, the inhibitor is transported to the liver cytosol in the free form in the blood and permeated into the lysosomes, where it binds to, and inactivates the enzyme
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
i.e. E-64, irreversible
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
95% inhibition at 0.01 mM
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
-
YFLLR
-
0.05 mM, 30% inhibition
YFLTF
-
0.05 mM, 29% inhibition
YKLLR
-
0.05 mM, 72% inhibition
YLLFW
-
0.05 mM, 37% inhibition
YLYLF
-
0.05 mM, 40% inhibition
YWFTF
-
0.05 mM, 43% inhibition
YWLLR
-
0.05 mM, 73% inhibition
YWYYL
-
0.05 mM, 20% inhibition
YYLLR
-
0.05 mM, 56% inhibition
Z-Phe-Phe-CH2F
-
i.e. inhibitor I, blocks sea urchin embryogenesis. Complete arrest of cell division is obtained when the embryos are incubated with 100 microM of inhibitor I
Z-Phe-Tyr-CHO
-
specifically inhibits cathepsin L
-
Zn(CH3COO)2
-
-
Zn2+
-
10% residual activity at 1 mM
Zn2+
-
1 mM, complete loss of activity
Zn2+
A5HJW4
14.75% residual activity at 5 mM
Mn2+
-
65% residual activity at 1 mM
additional information
-
in vivo inhibitor from bovine skeletal muscle, purification, MW 30000 Da
-
additional information
-
no inhibition by pepstatin, phenylmethane sulfonyl fluoride
-
additional information
-
MHC class II-associated invariant chain fragment from human kidney that has inhibitory effect on the enzyme
-
additional information
Agama stellio stellio
-
the enzyme is inhibited by cysteine proteases inhibitors
-
additional information
-
no inhibition with 0.14 mM (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate, (2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate, or (2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
additional information
-
not inhibited by EDTA
-
additional information
-
insensitive to K+, phenylmethylsulfonylfluoride and pepstatin A
-
additional information
-
not inhibited by N-(L-3-trans-(propylcarbamoyl)oxilane-2-carbonyl)-L-isoluecyl-L-proline (CA-074)
-
additional information
-
heparin cofactor II and plasminogen activator inhibitor 1 do not inhibit cathepsin L
-
additional information
-
native cathepsin L was completely inhibited by 0.001, 0.004, or 0.01 mM cathepsin L propeptide (10 min, pH 6.5, room temperature)
-
additional information
-
histones do not inhibit cathepsin L activity even at a 100fold molar excess (0.00215 mM histone concentration)
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
2-mercaptoethanol
-
strong activation of hydrolysis of insulin or albumin, at pH 4.0 and at pH 5.5
2-mercaptoethanol
-
enhances activity
7beta-hydroxycholesterol
-
significantly enhances cathepsin L in cells from healthy donors but not in cells from coronary artery disease patients
ATP
-
activates
ATP
-
maximal activity in presence of EDTA
Brij 35
A5HJW4
329.61% relative activity at 0.01% (v/v)
CoA
-
activates
Cys
-
strong activation of hydrolysis of insulin or albumin, at pH 4.0 and at pH 5.5
Cys
-
activates
Cys
-
activates
Cys
-
150 mM, required for full activation
Cystatin
-
activates
-
cysteamine
-
strong activation of hydrolysis of insulin or albumin, at pH 4.0 and at pH 5.5
cysteine
-
activation with 10 mM cysteine-HCl for 2 h at 37C
dibutyryl-cAMP
-
treatment of cells for identification of formerly N-linked glycopeptides. Treatment results in upregulation of follistatin-related protein 1, cathepsin L, and neuroblastoma suppressor of tumorigenicity, and the downregulation of tenascin C and cationin-dependent mannose-6-phosphate receptor
dithiothreitol
-
strong activation of hydrolysis of insulin or albumin, at pH 4.0 and at pH 5.5
dithiothreitol
-
0.3 mM, slight activation
dithiothreitol
-
enhances activity
dithiothreitol
-
70% activation with 1.5 mM
dithiothreitol
-
325% activity at 2 mM dithiothreitol
dithiothreitol
-
172% activity in the presence of 2 mM dithiothreitol and 1 mM EDTA, dithiothreitol alone does not inhibit activity
dithiothreitol
-
1 mM, 110% of initial activity
dithiothreitol
E5DHH4
stimulates at 2 mM
dithiothreitol
-
proteolytic activity requires presence of dithiothreitol. Autoproteolytic maturation of 68000 Da precursor to 61000 Da mature enzyme in presence of dithiothreitol
EDTA
-
essential for activity
EDTA
-
activates
EDTA
-
enhances activity
EDTA
-
1 mM, 106% of initial activity
glutathione
-
strong activation of hydrolysis of insulin or albumin, at pH 4.0 and at pH 5.5
Heparin sulfate
-
heparin sulfate (0.02 mg/ml) has no detectable effect on the rate of hydrolysis of the substrate at 0.0025 mM while it increases by 10fold the rate of substrate hydrolysis at 0.05 mM
protegrin-3
-
a porcine cathelicidin, molecular weight 11.7 kDa. The cathelin-like domain efficiently activates human cathepsin L. Partial deletion of the L2 loop of cathelin-like domain, a structurally equivalent region important ininteraction of cystatins with proteases, significantly decreases its activating effect on cathepsin L. Proposal of a complex model based on this functional loop, with the cathelin-like domain fitting into the active cleft of the enzyme in an analogous way as cystatin B does
-
proteinase inhibitor for serine protease
-
113% activity at 0.1 g/l
-
SDS
A5HJW4
201.87% relative activity at 0.01% (v/v)
Soybean trypsin inhibitor
-
activates
-
thiol-reducing agent
-
required for hydrolysis of benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
thiol-reducing agent
-
required
-
thiol-reducing reagent
Agama stellio stellio
-
required for activation
-
Triton X-100
A5HJW4
208.82% relative activity at 0.05% (v/v)
Tween 20
A5HJW4
337.68% relative activity at 0.01% (v/v)
Urea
-
enhances hydrolysis of azocasein
L-cysteine
-
114% activity at 5 mM
additional information
-
cell treatment with lipopolysaccharids induces expression of cytoplasmic CatL
-
additional information
-
under moderate hypoxic conditions of 1% O2, intracellular expression of cathepsin L is up-regulated. Hypoxia significantly increases only the expression of the transcript which contains the complete internal ribosome entry site, but inhibits promoter activity
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00045
2-aminobenzoyl-Ala-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00016
2-aminobenzoyl-Arg-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00071
2-aminobenzoyl-Asn-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00075
2-aminobenzoyl-Gln-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0025
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0022
2-aminobenzoyl-Glu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0011
2-aminobenzoyl-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0023
2-aminobenzoyl-Gly-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00035
2-aminobenzoyl-His-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00023
2-aminobenzoyl-Ile-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0026
2-aminobenzoyl-Lys-Arg-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.005
2-aminobenzoyl-Lys-Asn-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.035
2-aminobenzoyl-Lys-Asp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0085
2-aminobenzoyl-Lys-Gln-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0097
2-aminobenzoyl-Lys-Glu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0096
2-aminobenzoyl-Lys-Gly-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0034
2-aminobenzoyl-Lys-His-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00017
2-aminobenzoyl-Lys-Ile-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00095
2-aminobenzoyl-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00018
2-aminobenzoyl-Lys-Leu-Arg-Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0002
2-aminobenzoyl-Lys-Leu-Arg-Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00027
2-aminobenzoyl-Lys-Leu-Arg-Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0017
2-aminobenzoyl-Lys-Leu-Arg-Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00017
2-aminobenzoyl-Lys-Leu-Arg-Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0002
2-aminobenzoyl-Lys-Leu-Arg-His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0004
2-aminobenzoyl-Lys-Leu-Arg-Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00023
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00017
2-aminobenzoyl-Lys-Leu-Arg-Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00019
2-aminobenzoyl-Lys-Leu-Arg-Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00019
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00072
2-aminobenzoyl-Lys-Leu-Arg-Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00024
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00014
2-aminobenzoyl-Lys-Leu-Arg-Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00013
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00035
2-aminobenzoyl-Lys-Leu-Arg-Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00015
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00013
2-aminobenzoyl-Lys-Leu-Arg-Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00023
2-aminobenzoyl-Lys-Leu-Arg-Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0015
2-aminobenzoyl-Lys-Leu-Asn-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0038
2-aminobenzoyl-Lys-Leu-Asp-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00056
2-aminobenzoyl-Lys-Leu-Gln-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0055
2-aminobenzoyl-Lys-Leu-Glu-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00026
2-aminobenzoyl-Lys-Leu-Gly-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00021
2-aminobenzoyl-Lys-Leu-His-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00017
2-aminobenzoyl-Lys-Leu-Ile-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00017
2-aminobenzoyl-Lys-Leu-Lys-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00047
2-aminobenzoyl-Lys-Leu-Met-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.006
2-aminobenzoyl-Lys-Leu-Pro-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0011
2-aminobenzoyl-Lys-Leu-Ser-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00055
2-aminobenzoyl-Lys-Leu-Thr-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00028
2-aminobenzoyl-Lys-Leu-Val-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0006
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0028
2-aminobenzoyl-Lys-Met-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00026
2-aminobenzoyl-Lys-Phe-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0067
2-aminobenzoyl-Lys-Pro-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.012
2-aminobenzoyl-Lys-Ser-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0049
2-aminobenzoyl-Lys-Thr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0038
2-aminobenzoyl-Lys-Trp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00042
2-aminobenzoyl-Lys-Tyr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00059
2-aminobenzoyl-Lys-Val-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.0034
2-aminobenzoyl-Val-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
-
0.00016
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.000037
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.000073
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp
-
pH and temperature not specified in the publication
-
0.000063
Abz-PRKQLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.006
benzoyl-Phe-Val-Arg-4-methylcoumarin 7-amide
-
-
0.0176
benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin
-
pH 6.5
0.014
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
0.081
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.0013
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.0098
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
0.007
Benzyloxycarbonyl-Lys-Arg
-
pH 6.5
0.01
benzyloxycarbonyl-Lys-p-nitrophenyl ester
-
-
0.0007
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0011
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0011
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed Escherichia coli
0.00125
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.00168
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0017
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed in mouse myeloma cells
0.0018
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0022
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0022
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0024
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0045
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.006
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.007
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.03416
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.0011
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
0.0012
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.0014
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
Agama stellio stellio
-
-
0.0014
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/DELTAE286-E289
0.0015
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/M274L/D275N/G277A/V278M
0.0017
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/DELTAE286-N293
0.00825
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
0.0087
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.0157
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
pH 6.5
0.00033
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
0.00037
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.01 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.00041
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.005 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.00044
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.001 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.00046
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.00047
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.02 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.00695
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
-
0.01242
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
-
0.0208
Leu-Trp-Met-Arg-Phe-Ala
-
-
0.0825
leucine enkephalin
-
-
0.1096
methionine enkephalin-Arg-Phe
-
-
-
0.069
N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin
-
pH 5.5, 37C
0.04371
Pro-Phe-Arg-4-methylcoumarin 7-amide
-
-
0.005
succinyl-Ala-Phe-Lys-4-methylcoumarin 7-amide
-
-
0.1417
tert-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
5.3
2-aminobenzoyl-Ala-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.8
2-aminobenzoyl-Arg-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.5
2-aminobenzoyl-Asn-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.8
2-aminobenzoyl-Gln-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Glu-Glu-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4
2-aminobenzoyl-Glu-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.2
2-aminobenzoyl-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.1
2-aminobenzoyl-Gly-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
5.9
2-aminobenzoyl-His-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.3
2-aminobenzoyl-Ile-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.2
2-aminobenzoyl-Lys-Arg-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Asn-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Asp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.7
2-aminobenzoyl-Lys-Gln-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Glu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.5
2-aminobenzoyl-Lys-Gly-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.3
2-aminobenzoyl-Lys-His-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.3
2-aminobenzoyl-Lys-Ile-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.1
2-aminobenzoyl-Lys-Leu-Ala-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.7
2-aminobenzoyl-Lys-Leu-Arg-Arg-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
6.3
2-aminobenzoyl-Lys-Leu-Arg-Asn-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
5.8
2-aminobenzoyl-Lys-Leu-Arg-Gln-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.9
2-aminobenzoyl-Lys-Leu-Arg-Glu-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.4
2-aminobenzoyl-Lys-Leu-Arg-Gly-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
7.3
2-aminobenzoyl-Lys-Leu-Arg-His-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.9
2-aminobenzoyl-Lys-Leu-Arg-Ile-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.1
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ala-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Arg-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.3
2-aminobenzoyl-Lys-Leu-Arg-Ser-Asn-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.2
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gln-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.1
2-aminobenzoyl-Lys-Leu-Arg-Ser-Glu-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.8
2-aminobenzoyl-Lys-Leu-Arg-Ser-Gly-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.7
2-aminobenzoyl-Lys-Leu-Arg-Ser-His-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.4
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ile-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Pro-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4.6
2-aminobenzoyl-Lys-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.2
2-aminobenzoyl-Lys-Leu-Arg-Ser-Val-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
5.5
2-aminobenzoyl-Lys-Leu-Arg-Val-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.1
2-aminobenzoyl-Lys-Leu-Asn-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.2
2-aminobenzoyl-Lys-Leu-Asp-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.9
2-aminobenzoyl-Lys-Leu-Gln-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.6
2-aminobenzoyl-Lys-Leu-Glu-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Leu-Gly-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.3
2-aminobenzoyl-Lys-Leu-His-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Leu-Ile-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
3.1
2-aminobenzoyl-Lys-Leu-Lys-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Leu-Met-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.1
2-aminobenzoyl-Lys-Leu-Pro-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.5
2-aminobenzoyl-Lys-Leu-Ser-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.3
2-aminobenzoyl-Lys-Leu-Thr-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.5
2-aminobenzoyl-Lys-Leu-Val-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.9
2-aminobenzoyl-Lys-Lys-epsilon-amino-caproic acid-Glu-Leu-Lys-Leu-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
4
2-aminobenzoyl-Lys-Met-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
13.5
2-aminobenzoyl-Lys-Phe-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.2
2-aminobenzoyl-Lys-Pro-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.9
2-aminobenzoyl-Lys-Ser-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.4
2-aminobenzoyl-Lys-Thr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
1.9
2-aminobenzoyl-Lys-Trp-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
7.8
2-aminobenzoyl-Lys-Tyr-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
6.4
2-aminobenzoyl-Lys-Val-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
2.1
2-aminobenzoyl-Val-Leu-Arg-Ser-Ser-Lys-Gln-N-(2,4-dinitrophenyl)ethylenediamine
-
50 mM Na-acetate, 100 mM NaCl, 2.5 mM EDTA, pH 5.5, 37C
0.49
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.37
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.51
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp
-
pH and temperature not specified in the publication
-
0.46
Abz-PRKQLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
-
0.01
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
0.5
benzyloxycarbonyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
1.62
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
17.6
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
27.2
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
19.8
benzyloxycarbonyl-Lys-p-nitrophenyl ester
-
-
5.53
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
9.5
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
10
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
15.8
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
17
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
20
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
25.8
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
26
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
30
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
30
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
-
39
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed Escherichia coli
50
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide
-
recombinant enzyme expressed in mouse myeloma clls
1.7
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
2 - 3.7
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
5.4
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
6.2
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
Agama stellio stellio
-
-
9
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/M274L/D275N/G277A/V278M
18
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/DELTAE286-E289
20.5
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L67Y/A205L
30
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
mutant enzyme T223V/DELTAE286-N293
46
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
wild type enzyme
2.64
benzyloxycarbonyl-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
0.39
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.01 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.43
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.02 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.45
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.005 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.52
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C; in the presence of 0.001 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
1.01
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
0.89
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
-
1.07
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
-
26.6
Leu-Trp-Met-Arg-Phe-Ala
-
-
33.9
leucine enkephalin
-
-
43.2
methionine enkephalin-Arg-Phe
-
-
-
12.8
N-carbobenzoxy-L-phenylalanine-L-arginine 7-amido-4-methylcoumarin
-
pH 5.5, 37C
1.52
Pro-Phe-Arg-4-methylcoumarin 7-amide
-
-
2.48
tert-butyloxycarbonyl-Ala-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
1.67
tert-butyloxycarbonyl-Val-Leu-Lys-4-methylcoumarin 7-amide
-
-
1.17
tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin
-
wild type enzyme FehCL2, in PBS, pH 7.3, and 100 mM sodium acetate buffer, pH 5.5, each containing 2.5 mM dithiothreitol and 2.5 mM EDTA
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
2900
Abz-PR-acetyl-K-QLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
0
6700
Abz-PRKQLAT-acetyl-K-AARKSAK-Dnp
-
pH and temperature not specified in the publication
0
5300
Abz-PRKQLATKAAR-dimethyl-K-SAK-Dnp
-
pH and temperature not specified in the publication
0
6100
Abz-PRKQLATKAARKSAK-Dnp
-
pH and temperature not specified in the publication
0
18.1
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
74796
182
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
74796
781
benzoyl-L-Phe-L-Val-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
74796
38.3
D-Val-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
34187
308
D-Val-Leu-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
34187
5420
D-Val-Leu-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
34187
152
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
5065
474
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
5065
999.8
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.02 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
5065
1088
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.01 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
5065
1119
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.001 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
5065
1121
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in the presence of 0.005 mg/ml heparin sulfate, in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
5065
1187
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
5065
3148
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
5065
149
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
35935
211
L-Pro-L-Phe-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
35935
71.6
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0
155.3
L-Val-L-Leu-L-Arg-7-amido-4-methylcoumarin
-
in 50 mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 37C
0
16.6
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
33.8
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
119
tert-butyloxycarbonyl-L-Ala-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
10.1
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
11.3
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
75.2
tert-butyloxycarbonyl-L-Asp-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
6.75
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
40622
1390
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
40622
7220
tert-butyloxycarbonyl-L-Val-L-Leu-L-Lys-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
40622
5.01
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
22.4
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
52.7
tert-butyloxycarbonyl-L-Val-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
0
24.4
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
8882
38.5
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
wild type enzyme, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
8882
84.3
tosyl-Gly-L-Pro-L-Arg-7-amido-4-methylcoumarin
-
mutant enzyme L69W, at pH 5.5, in the presence of 10 mM cysteine-HCl, at 37C
8882
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0004
(2R,3R)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0048
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0059
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0048
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0059
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0529
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.026
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0101
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0101
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0187
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
0.0178
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]aziridine-2,3-dicarboxylic acid
-
-
0.0178
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0153
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
0.0159
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
0.0064
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(R)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.000013
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(S)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0014
(2S,3S)-dibenzyl-1-[biotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
0.0042
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0042
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.004
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0216
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0147
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0038
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0044
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.006
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
0.0038
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
0.0044
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0152
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0166
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
0.0058
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0071
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0058
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R+S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0064
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-pipecolyl]-aziridine-2,3-dicarboxylate
-
-
0.0158
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0024
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0024
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
0.0077
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
0.0079
(2S,3S+2R,3R)-dibenzyl-1-[desthiobiotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
0.0053
(E)N-[(S)1-[(S)2-cyano-1-pyrrolidinecarbonyl]-3-methylbutyl]-2,3-diphenylacrylamide
-
23C, pH 6.0
0.023
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([2-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.002
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0023
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0025
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.012
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-3-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-4-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.013
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(thiophen-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[methyl(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(methylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.031
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(phenylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.016
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-([[4-([[(dimethylamino)methyl]sulfonyl]amino)phenyl]carbonyl]amino)-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.029
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([2-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0078
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-fluoro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0072
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.017
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([4-[(ethylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.016
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0078
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.014
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0059
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.011
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-(methylsulfamoyl)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0091
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-([[4-(1-methylethyl)-1,3-thiazol-2-yl]sulfonyl]amino)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.027
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-sulfamoylphenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.024
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methyl-1H-imidazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methylethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0084
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2-methylphenyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.027
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0087
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methylpyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.017
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(5-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.01
1,4-anhydro-3,5,6-trideoxy-3-[[4-methyl-N-(thiophen-3-ylcarbonyl)-L-leucyl]amino]-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.00097
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0011
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.015
1,4-anhydro-3-[[(2S)-2-[([4-[(benzylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.021
1,4-anhydro-3-[[(2S)-2-[([4-[(butylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.012
1,4-anhydro-3-[[(2S)-2-[([4-[(cyclopropylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.023
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-chloropyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0085
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0068
1,4-anhydro-3-[[(2S)-2-[[(4-[[(3-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0079
1,4-anhydro-3-[[(2S)-2-[[(4-[[(4-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.064
1,4-anhydro-3-[[(2S)-2-[[(4-[[(cyclohexylmethyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0095
3-[[(2S)-2-[([3-acetyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0091
3-[[(2S)-2-[[(4-[[(4-aminophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
100 mM sodium acetate, 1 mM EDTA, 1 mM DTT, 0.1% PEG 4000, pH 5.5
0.0000022
azepanone
-
-
0.00000057
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-naphthylen-2-yl)amide
-
-
0.0000017
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenyl-ethyl)amide
-
-
0.03
biphenyl-4-yl-acetylasparagine-D-Arg-Phe-Phe-NH2
-
pH 5.5, 25C
0.00021
biphenyl-4-yl-acetylcysteine-D-Arg-Abu-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.0039
biphenyl-4-yl-acetylcysteine-D-Arg-Arg-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.081
biphenyl-4-yl-acetylcysteine-D-Arg-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.000021
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.00017
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-Phe-NH2
-
pH 5.5, 25C
0.000067
biphenyl-4-yl-acetylcysteine-D-Arg-Trp-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.000045
biphenyl-4-yl-acetylcysteine-D-Arg-Tyr-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.00027
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Leu-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.00024
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Met-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.000019
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.00021
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(3-phenylpropyl)amide
-
pH 5.5, 25C
0.0066
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(benzyl)amide
-
pH 5.5, 25C
0.00007
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-Phe-NH2
-
pH 5.5, 25C
0.0002
biphenyl-4-yl-acetylmethylcysteine-D-Orn-Phe-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.00093
biphenyl-4-yl-acetylmethylcysteine-Gly-Phe-Phe-NH2
-
pH 5.5, 25C
0.00049
biphenyl-4-yl-acetylnorvaline-D-Arg-Phe-N-(2-phenylethyl)amide
-
pH 5.5, 25C
0.07
biphenyl-4-yl-acetylserine-D-Arg-Phe-Phe-NH2
-
pH 5.5, 25C
0.000023
biphenylacetyl-(N6-biphenylacetyl)-Lys-D-Arg-Tyr-N-phenylethyl
-
pH and temperature not specified in the publication
0.000511
biphenylacetyl-(N6-biphenylacetyl)Lys-D-Arg-Phe-N-phenylethyl
-
pH and temperature not specified in the publication
0.000019
biphenylacetyl-MCys-D-Arg-Phe-N-phenylethyl
-
pH and temperature not specified in the publication
0.0000026
cathepsin K propeptide
-
pH 5.5, room temperature
-
0.00000012
cathepsin L propeptide
-
pH 5.5, room temperature
-
0.00000046
cathepsin S propeptide
-
pH 5.5, room temperature
-
0.0000000073
chagasin
-
-
-
0.0000022
chagasin mutant deltaT31-T32
-
-
-
0.000000045
chagasin mutant P30A
-
-
-
0.0000000039
chagasin mutant T31A
-
-
-
0.0000000018
chagasin mutant T31A/T32A
-
-
-
0.0000000049
chagasin mutant T31S
-
-
-
0.0000000097
chagasin mutant T31V
-
-
-
0.0000000068
chagasin mutant T31Y
-
-
-
0.000000014
chagasin mutant T32A
-
-
-
0.000000032
chagasin mutant T32S
-
-
-
0.00000002
chagasin mutant T32V
-
-
-
0.0000000027
chagasin mutant T32Y
-
-
-
0.000000825
chagasin mutant W93A
-
-
-
0.00000005
cystatin A
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000021
cystatin A
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000005
cystatin B
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000046
cystatin B
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000008
cystatin C
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000281
cystatin D
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.0000065
cystatin D
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000019
cystatin E/M
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000021
cystatin F
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000049
cystatin F
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000178
cystatin M/E
-
0.1 M acetate pH 5.5, 1 mM EDTA, 2 mM dithiothreitol, 100 mg/ml bovine serum albumin, 10 min
-
0.00000051
cystatin SA
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.00000027
cystatin SN
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
-
0.0000000072
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
pH 6.0, 25C
-
0.0000000101
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
pH 6.0, 25C
-
0.0107
KAPR-acetyl-K-QLATKAARKSAPA
-
pH and temperature not specified in the publication
-
0.00502
KAPRKQLAT-acetyl-K-AARKSAPA
-
pH and temperature not specified in the publication
-
0.00455
KAPRKQLATKAAR-dimethyl-K-SAPA
-
pH and temperature not specified in the publication
-
0.0045
KAPRKQLATKAARKSAPA
-
pH and temperature not specified in the publication
-
0.05241
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
in 50mM Na2HPO4, pH 6.5, 100 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol, at 25C
0.0043
N-(4-biphenylacetyl)-S-methylcysteine-(D)-Arg-Phe-beta-phenethylamide
-
wild type enzyme
0.00000043
naphthalene-2-carboxylic acid ((S)-2-naphthalen-2-yl-1-[(S)-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]ethyl)amide
-
-
0.0000014
naphthoic-1-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.0095
ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37C, in 0.1 M sodium acetate buffer, pH 5.5
0.005
ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37C, in 0.1 M sodium acetate buffer, pH 5.5
0.0002
ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37C, in 0.1 M sodium acetate buffer, pH 5.5
0.01
ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
at 37C, in 0.1 M sodium acetate buffer, pH 5.5
0.00000000149
p41-fragment-human
-
substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.00000000552
p41-fragment-human
-
wild-type, substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.0000000101
p41-fragment-human
-
G139R mutant, substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.00000000722
p41-fragment-mouse
-
substrate: benzyloxycarbonyl-Phe-Arg-4-methylcoumarin-7-amide, production rate of 7-amino-4-methylcoumarin measured, excitation and emission wavelengths of 370 and 460 nm, pseudo first order reaction conditions (inhibitor concentration at least 10-fold higher than enzyme concentration)
-
0.0000006
Phe-Tyr-(OBut)-COCHO
-
pH and temperature not specified in the publication
-
0.000005
quinoline-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.0000082
quinoline-8-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
0.00013
RKLLW-NH2
-
pH 5.5, 37C
0.0000007
testican-1
-
-
-
0.00000014
thyroglobulin type-1 domain
-
0.1 M sodium acetate, 1 mM EDTA, 24C
-
0.00000059
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
-
50 mM sodium acetate, 1 mM dithiothreitol, pH 5.0, 24C
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00246
(2E)-2-[(2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000118
(2E)-2-[(3-bromophenyl)(3,4,5-trifluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000415
(2E)-2-[(3-bromophenyl)(3,5-dichlorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000594
(2E)-2-[(3-bromophenyl)(3,5-difluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000131
(2E)-2-[(3-bromophenyl)(3-chlorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.00025
(2E)-2-[(3-bromophenyl)(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000224
(2E)-2-[(3-bromophenyl)(3-methylphenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(3-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000327
(2E)-2-[(3-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000796
(2E)-2-[(3-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.00216
(2E)-2-[(3-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000465
(2E)-2-[(3-bromophenyl)[3-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000521
(2E)-2-[(3-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(4-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00332
(2E)-2-[(4-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.00457
(2E)-2-[(4-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
(2E)-2-[(4-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000096
(2E)-2-[[3,5-bis(trifluoromethyl)phenyl](3-bromophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000019
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
-
-
0.0026
(2Z)-2-[(2-bromophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
(2Z)-2-[(2-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
(2Z)-2-[(2-fluorophenyl)(phenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.000233
(2Z)-2-[(3-bromo-2-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.000114
(2Z)-2-[(3-bromo-4-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000632
(2Z)-2-[(3-bromophenyl)(2,3,4,5-tetrafluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000838
(2Z)-2-[(3-bromophenyl)(2,3-difluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.00061
(2Z)-2-[(3-bromophenyl)(2,6-difluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.00161
(2Z)-2-[(3-bromophenyl)(2-chlorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.0000305
(2Z)-2-[(3-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
(2Z)-2-[(3-bromophenyl)(2-methylphenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00045
1,3-dihydro-pyrrolo[3,4-b]quinoline-2-carbonitrile
-
IC50: 0.00045 mM
0.00001
1-cyano-3-azetidinyl cyclohexylmethyl ether
-
IC50: 0.00001 mM
0.00043
1-cyanoazetidine
-
IC50: 0.00043 mM
0.004
1-cyanopyrrolidine
-
IC50: 0.004 mM
0.000007
2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylate
-
-
0.0012
2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0011
2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00078
2-cyano-4-(cyclohexylmethoxy)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000426
2-cyano-4-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0003
2-cyano-4-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00046
2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00036
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000276
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[4.5]dec-8-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00139
2-cyano-N-methyl-4-[(spiro[3.5]non-7-ylmethyl)amino]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00012
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00012
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00044
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00033
2-cyano-N-methyl-4-[[1-(1-methylethyl)piperidin-4-yl]methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0007
2-cyano-N-[(1-methyl-4-phenylpiperidin-4-yl)methyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00048
2-cyano-N-[(1R)-2-pyridin-2-yl-1-(pyrrolidin-1-ylmethyl)ethyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00084
2-cyano-N-[5-[(1-methylpiperidin-4-yl)oxy]biphenyl-2-yl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000044
2-furancarbonyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.000007
2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylic 3,4-dihydroquinoline-1(2H)-carboxylic anhydride
-
in 1 mM EDTA, 5 mM cysteine at pH 5.5
0.01
2-[bis(3-bromophenyl)methylidene]-N-ethylhydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
2-[bis(3-bromophenyl)methylidene]-N-phenylhydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00487
2-[bis(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
0.01
2-[bis(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.01
2-[bis(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.00893
2-[cyclohexyl(methyl)amino]-4H-3,1-benzothiazin-4-one
-
37C, pH 6.0
0.00001
3-(benzyloxy)-1-cyanoazetidine
-
IC50: 0.00001 mM
0.0025
4-[(1-acetylpiperidin-4-yl)methoxy]-2-cyano-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00028
5-bromo-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000096
6-(4-chlorobenzyl)-7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00084
6-(4-chlorobenzyl)-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00026
6-(4-chlorobenzyl)-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00037
6-(4-chlorobenzyl)-7-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00004
6-(4-chlorobenzyl)-7-[2-(3-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0052
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
0.000057
acetyl-prolyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.000019
acetyl-prolyl-prolyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.000054
benzyl 1-cyano-3-pyrrolidinylcarbamate
-
IC50: 0.000054 mM
0.000163
benzyloxycarbonyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.000056
cathepsin L inhibitor 1
-
thiocarbazate cathepsin L inhibitor, 20 mM sodium acetate, 1 mM EDTA, 5 mM cysteine at pH 5.5
0.000056
CID 16725315
-
pH and temperature not specified in the publication
0.1
diethyl-cyanamide
-
IC50 is above 0.1 mM
0.00002
isonicotinyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.0008
LFLTR-NH2
-
IC50: 0.0008 mM
0.0005
LLLTR-NH2
-
IC50: 0.0005 mM
0.0386
methyl 5-acetyloxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
pH 5.5, 22C
0.0616
methyl 5-hydroxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
pH 5.5, 22C
0.000048
morpholinylsuccinyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.00175
N-(1-cyano-3-pyrrolidinyl)benzamide
-
IC50: 0.00175 mM
0.00008
N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide
-
IC50: 0.00008 mM
0.00085
N-(1-cyano-3-pyrrolidinyl)[1,1'-biphenyl]-4-carboxamide
-
IC50: 0.00085 mM
0.000064
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.0001
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)oxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00027
N-benzyl-2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.01
N-benzyl-2-[bis(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
IC50 above 0.01 mM, pH and temperature not specified in the publication
0.023
N-[(1-cyano-2-pyrrolidinyl)methyl]benzamide
-
IC50: 0.023 mM
0.0115
N-[(1-cyano-2-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.0115 mM
0.00065
N-[(1-cyano-3-azetidinyl)methyl]benzamide
-
IC50: 0.00065 mM
0.00005
N-[(1-cyano-3-azetidinyl)methyl]benzenesulfonamide
-
IC50: 0.00005 mM
0.000006
N-[(1-cyano-3-azetidinyl)methyl]cyclohexanecarboxamide
-
IC50: 0.000006 mM
0.00035
N-[(1-cyano-3-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.00035 mM
0.00015
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.00084
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylpropyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.0015
N-[(1S)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
0.000027
nicotinyl-leucyl-leucyl-leucinal
-
pH 5.0, 37C
0.0006
RKLLW-NH2
-
IC50: 0.0006 mM
0.014
RKLWD-NH2
-
IC50: 0.014 mM
0.0008
RKLWL-NH2
-
IC50: 0.0008 mM
0.00011
S-(2-oxo-1-phenylpyrrolidin-3-yl) 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
0.000041
S-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
0.000001
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
pH 5.5, preincubation with enzyme 4 h before substrate addition
0.0000075
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
pH 5.5, preincubation with enzyme 1 h before substrate addition
0.000056
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
0.000056
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
pH 5.5
0.000115
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]hydrazinecarbothioate
-
-
0.033
S-{2-[(2-ethylphenyl)amino]-2-oxoethyl} 2-[(2R)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
thiocarbazate cathepsin L inhibitor, 1 mM EDTA, 5 mM cysteine at pH 5.5
0.00222
(2Z)-2-[(4-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
pH and temperature not specified in the publication
additional information
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
-
KI value is above 5 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.0004
2-cyano-4-[(2-cyclopentylethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
2-cyano-4-[(6,8-dioxaspiro[3.5]non-7-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
IC50 is above 0.001 mM, determined by a fluorometric assay with recombinant catL employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.002
2-cyano-4-[(cyclohexylmethyl)(methyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-4-[(cyclohexylmethyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
IC50 is above 0.002 mM, inhibition are determined by a fluorometric assay with recombinant Cat L
0.00001
2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-N-(2-phenylethyl)-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-4-[[(4,4-difluorocyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
IC50 is above 0.003 mM, inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-4-[[(4,4-dimethylcyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
0.00051
2-cyano-N-(1-methyl-4-phenylpiperidin-4-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-N-(2-phenylethyl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
2-cyano-N-(4,5-dimethoxybiphenyl-2-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
IC50 is above 0.003 mM inhibition are determined by a fluorometric assay with recombinant Cat L
0.00015
3-[(benzyloxy)methyl]-1-cyanopyrrolidine
-
IC50: 0.00015 mM
additional information
3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00087
4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
inhibition are determined by a fluorometric assay with recombinant Cat L
additional information
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzoic acid
-
KI value is above 2 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00032
6-(4-chlorobenzyl)-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(2-cyclooctylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000023
6-(4-chlorobenzyl)-7-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(2-piperidin-1-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000018
6-(4-chlorobenzyl)-7-(3,3-dimethylbutyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(3-cyclohexylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-(4-chlorobenzyl)-7-(4,4-dimethylpentyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.000086
6-(4-chlorobenzyl)-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(1-acetylpiperidin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 4 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(4-acetyl-1,4-diazepan-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
0.0068
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)-3-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 2 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 4 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
0.0023
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 0.01 mM, Z-Phe-Arg-7-amino-4-methylcumarin as substrate
0.0062
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
IC50 is above 1 M, with Z-Phe-Arg-7-amido-4-methylcoumarin as substrate
additional information
7-(2-cyclohexylethyl)-6-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-(phenoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
additional information
7-(2-cyclohexylethyl)-6-[(phenylamino)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
KI value is above 1 microM, inhibition profiles are determined by a fluorometric assay with recombinant CAT L employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate
0.00079
7-(2-cyclohexylethyl)-6-[(pyridin-2-yloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
inhibition profiles are determined by a fluorometric assay with recombinant CAT K employing Z-Phe-Arg-7-amido-4-methylcoumarin as synthetic substrate